<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00083889</url>
  </required_header>
  <id_info>
    <org_study_id>A6181034</org_study_id>
    <nct_id>NCT00083889</nct_id>
    <nct_alias>NCT00098657</nct_alias>
  </id_info>
  <brief_title>SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma</brief_title>
  <official_title>A Phase 3, Randomized Study Of SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether SU011248 has activity and is safe compared to
      interferon-alfa as first-line therapy in patients with metastatic renal cell carcinoma (RCC).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS), Core Radiology Assessment</measure>
    <time_frame>Day 28 of each 6-week cycle: duration of treatment phase</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS), Investigator's Assessment</measure>
    <time_frame>Day 28 of each 6-week cycle: duration of treatment phase</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response, Core Radiology Assessment</measure>
    <time_frame>Day 28 of each 6-week cycle: duration of treatment phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response, Investigator's Assessment</measure>
    <time_frame>Day 28 of each 6-week cycle: duration of treatment phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Clinic visit or telephone contact every 2 months until death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Tumor Progression (TTP), Core Radiology Assessment</measure>
    <time_frame>Randomization to first documentation of tumor progression: duration of treatment phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Tumor Progression (TTP), Investigator's Assessment</measure>
    <time_frame>Randomization to first documentation of tumor progression: duration of treatment phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DR), Core Radiology Assessement</measure>
    <time_frame>Day 28 of each cycle: duraton of treatment phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DR), Investigator's Assessment</measure>
    <time_frame>Day 28 of each cycle: duration of treatment phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FACT-Kidney Symptom Index-Disease Related Symptoms (FKSI-DRS) Subscale</measure>
    <time_frame>Day 1 &amp; 28 of each cycle: duration of treatment phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FACT-Kidney Symptom Index (FKSI) Subscale</measure>
    <time_frame>Day 1 &amp; 28 of each cycle: duration of treatment phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment of Cancer Therapy-General (FACT-G)</measure>
    <time_frame>Day 1 &amp; 28 of each cycle: duration of treatment phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment of Cancer Therapy-General (FACT-G): Physical Well Being (PWB) Subscale</measure>
    <time_frame>Day 1 &amp; 28 of each cycle: duration of treatment phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment of Cancer Therapy-General (FACT-G): Social/Family Well Being (SWB) Subscale</measure>
    <time_frame>Day 1 &amp; 28 of each cycle: duration of treatment phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment of Cancer Therapy-General (FACT-G): Emotional Well Being (EWB) Subscale</measure>
    <time_frame>Day 1 &amp; 28 of each cycle: duration of treatment phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment of Cancer Therapy-General (FACT-G): Functional Well Being (FWB) Subscale</measure>
    <time_frame>Day 1 &amp; 28 of each cycle: duration of treatment phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQoL Five Dimension (EQ-5D) Health State Index</measure>
    <time_frame>Day 1 &amp; 28 of each cycle: duration of treatment phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Euro-QoL Visual Analog Scale (EQ-VAS)</measure>
    <time_frame>Day 1 &amp; 28 of each cycle: duration of treatment phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of Soluble Proteins: Plasma VEGF-A, Plasma VEGF-C, Plasma sVEGFR-3, PLASMA IL-8, and PLASMA bFGF That May be Associated With Tumor Proliferation or Angiogenesis</measure>
    <time_frame>Day 1 &amp; Day 28, Cycle 1 to Cycle 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of Soluble Proteins: Plasma Basic Fibroblast Growth Factor (bFGF) That May be Associated With Tumor Proliferation or Angiogenesis</measure>
    <time_frame>Day 1 &amp; Day 28, Cycle 1 to Cycle 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental Cost Effectiveness Ratio (ICER)</measure>
    <time_frame>post study measurement</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough Concentrations of SU011248</measure>
    <time_frame>Day 28 of Cycle 1 to Cycle 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough Concentrations of Metabolite SU012662</measure>
    <time_frame>Day 28 of Cycle 1 to Cycle 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough Concentrations of SU011248 and Active Metabolite SU012662</measure>
    <time_frame>Day 28 of Cycle 1 to Cycle 4</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">750</enrollment>
  <condition>Carcinoma, Renal Cell</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon-alfa</intervention_name>
    <description>3 MIU first week, 6 MIU second week, and 9 MIU thereafter three times a week (non-consecutive days) until progression or unacceptable toxicity</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Roferon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SU011248</intervention_name>
    <description>50 mg orally daily for 4 weeks and 2 weeks off treatment until progression or unacceptable toxicity</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Sunitinib, SUTENT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed renal cell carcinoma of clear cell histology with metastases

          -  Evidence of measurable disease by radiographic technique

          -  Eastern Cooperative Oncology Group [ECOG] performance status of 0 or 1

        Exclusion Criteria:

          -  Prior systemic (including adjuvant or neoadjuvant) therapy of any kind for RCC

          -  History of or known brain metastases

          -  Serious acute or chronic illness or recent history of significant cardiac abnormality
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80040-0510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <zip>70433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Detoit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Mississippi</state>
        <zip>39705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Corinth</city>
        <state>Mississippi</state>
        <zip>38834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Southaven</city>
        <state>Mississippi</state>
        <zip>38671</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-9200</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10466</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111-2497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lismore</city>
        <state>New South Wales</state>
        <zip>2480</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>St. Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Woodville South</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Victoria</city>
        <zip>36184</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>20231-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90020-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y5L3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1S 2L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Paris</city>
        <state>Cedex 15</state>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Paris Cedex 13</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Saint Herblain</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Roma</city>
        <zip>00135</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Roma</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Roma</city>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Moczowego</city>
        <state>Warszawa</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80-210</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-115</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lodz</city>
        <zip>93-509</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-090</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>00-909</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-043</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Obninsk</city>
        <state>Kaluga Region</state>
        <zip>249036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>117836</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tomsk</city>
        <zip>634050</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Whitchurch</city>
        <state>Cardiff</state>
        <zip>CF14 2 TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>Lancashire</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Northwood</city>
        <state>Middlesex</state>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sutton Surrey</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6181034&amp;StudyName=SU011248%20Versus%20Interferon-Alfa%20As%20First-Line%20Systemic%20Therapy%20For%20Patients%20With%20Metastatic%20Renal%20Cell%20Carcinoma%20%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2004</study_first_submitted>
  <study_first_submitted_qc>June 3, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2004</study_first_posted>
  <results_first_submitted>September 16, 2009</results_first_submitted>
  <results_first_submitted_qc>November 6, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 10, 2009</results_first_posted>
  <last_update_submitted>January 19, 2010</last_update_submitted>
  <last_update_submitted_qc>January 19, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer Inc</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 101 medical centers took part in the study between 10 August 2004 and 19 September 2008.</recruitment_details>
      <pre_assignment_details>Subjects were to be followed until survival data was mature (median duration of follow-up: 123 weeks).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>SU011248</title>
          <description>50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered.</description>
        </group>
        <group group_id="P2">
          <title>IFN-α</title>
          <description>Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="375"/>
                <participants group_id="P2" count="375"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="375"/>
                <participants group_id="P2" count="360">15 subjects randomized to IFN-α discontinued before receiving their first dose of study medication.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0">Discontinuation crossover subjects: AEs 5,consent withdrawn 2, lack efficacy 13, sponsor decision 5.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="375"/>
                <participants group_id="P2" count="375"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="86"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="240"/>
                <participants group_id="P2" count="219"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Decision of sponsor</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized: did not take study drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Completed on marketed sunitinub</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Crossover to SU011248</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SU011248</title>
          <description>50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered.</description>
        </group>
        <group group_id="B2">
          <title>IFN-α</title>
          <description>Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="375"/>
            <count group_id="B2" value="375"/>
            <count group_id="B3" value="750"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="223"/>
                    <measurement group_id="B2" value="252"/>
                    <measurement group_id="B3" value="475"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="152"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="267"/>
                    <measurement group_id="B2" value="269"/>
                    <measurement group_id="B3" value="536"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-Free Survival (PFS), Core Radiology Assessment</title>
        <description>Progression-free survival (PFS) = time from randomization to first documentation of objective tumor progression or to death due to any cause, whichever occured first. If tumor progression data included more than 1 date, the first date was used. PFS = first event date minus the date of randomization + 1. On study included treatment plus 28-day follow-up periods.</description>
        <time_frame>Day 28 of each 6-week cycle: duration of treatment phase</time_frame>
        <population>Intent to treat (ITT) population: all patients who were randomized, with study drug assignment designated according to initial randomization, regardless of whether patients received study drug or received a different drug from that to which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>SU011248</title>
            <description>50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered.</description>
          </group>
          <group group_id="O2">
            <title>IFN-α</title>
            <description>Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival (PFS), Core Radiology Assessment</title>
          <description>Progression-free survival (PFS) = time from randomization to first documentation of objective tumor progression or to death due to any cause, whichever occured first. If tumor progression data included more than 1 date, the first date was used. PFS = first event date minus the date of randomization + 1. On study included treatment plus 28-day follow-up periods.</description>
          <population>Intent to treat (ITT) population: all patients who were randomized, with study drug assignment designated according to initial randomization, regardless of whether patients received study drug or received a different drug from that to which they were randomized.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="375"/>
                <count group_id="O2" value="375"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.3" lower_limit="46.4" upper_limit="58.3"/>
                    <measurement group_id="O2" value="22.1" lower_limit="17.1" upper_limit="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Unstratified analysis: Hazard Ratio (SU011248 vs IFN—α). Progression-free survival (PFS) was assessed in each treatment arm using the Kaplan-Meier method.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>p-value from 2-sided, unstratified test.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.5268</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4316</ci_lower_limit>
            <ci_upper_limit>0.6430</ci_upper_limit>
            <estimate_desc>Assuming proportional hazards, a hazard ratio les than 1 indicates a reduction in hazard rate in favor of SU011248; a hazard ratio greater than 1 indicates a reduction in favor of IFN-a.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified analysis: Hazard Ratio (SU011248 vs IFN—a).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.00001</p_value>
            <p_value_desc>p-value is from 2-sided, stratified test. Stratification factors were: Lactic Dehydrogenase (LDH) &gt; or &lt;= 1.5 x upper limit of normal, Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, and absence or presence of prior nephrectomy.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.5136</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4196</ci_lower_limit>
            <ci_upper_limit>0.6288</ci_upper_limit>
            <estimate_desc>Assuming proportional hazards, a hazard ratio less than 1 indicates a reduction in hazard rate in favor of SU011248: a hazard ratio greater than 1 indicates a reduction in favor of IFN—a.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response, Core Radiology Assessment</title>
        <description>Objective response (OR) = the number of patients with confirmed complete response (CR) and confirmed partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, relative to all randomized patients. CR was defined as the disappearance of all target lesions. PR was defined as a ≥ 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. Confirmed responses (CR or PR) = those that persisted on repeat imaging study &gt;= 4 weeks after initial documentation of response.</description>
        <time_frame>Day 28 of each 6-week cycle: duration of treatment phase</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>SU011248</title>
            <description>50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered.</description>
          </group>
          <group group_id="O2">
            <title>IFN-α</title>
            <description>Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response, Core Radiology Assessment</title>
          <description>Objective response (OR) = the number of patients with confirmed complete response (CR) and confirmed partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, relative to all randomized patients. CR was defined as the disappearance of all target lesions. PR was defined as a ≥ 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. Confirmed responses (CR or PR) = those that persisted on repeat imaging study &gt;= 4 weeks after initial documentation of response.</description>
          <population>ITT</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="375"/>
                <count group_id="O2" value="375"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
            <param_type>treatment difference</param_type>
            <param_value>30.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>25.31</ci_lower_limit>
            <ci_upper_limit>36.56</ci_upper_limit>
            <estimate_desc>95% confidence interval was calculated based on a normal distribution.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response, Investigator's Assessment</title>
        <description>Objective response (OR) = the number of patients with confirmed complete response (CR) and confirmed partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, relative to all randomized patients. CR was defined as the disappearance of all target lesions. PR was defined as a ≥ 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. Confirmed responses = those that persist on repeat imaging study &gt;= 4 weeks after initial documentation of response.</description>
        <time_frame>Day 28 of each 6-week cycle: duration of treatment phase</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>SU011248</title>
            <description>50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered.</description>
          </group>
          <group group_id="O2">
            <title>IFN-α</title>
            <description>Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response, Investigator's Assessment</title>
          <description>Objective response (OR) = the number of patients with confirmed complete response (CR) and confirmed partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, relative to all randomized patients. CR was defined as the disappearance of all target lesions. PR was defined as a ≥ 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. Confirmed responses = those that persist on repeat imaging study &gt;= 4 weeks after initial documentation of response.</description>
          <population>ITT</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="375"/>
                <count group_id="O2" value="375"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
            <param_type>treatment difference</param_type>
            <param_value>33.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>27.62</ci_lower_limit>
            <ci_upper_limit>39.69</ci_upper_limit>
            <estimate_desc>95% confidence interval was calculated based on a normal distribution.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>Overall survival (OS) = time from date of randomization to date of death due to any cause. For patients not expiring, survival time was censored at the last date they were known to be alive. Patients lacking data beyond randomization had their survival times censored at the date of randomization with a duration of 1 day.</description>
        <time_frame>Clinic visit or telephone contact every 2 months until death</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>SU011248</title>
            <description>50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered.</description>
          </group>
          <group group_id="O2">
            <title>IFN-α</title>
            <description>Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Overall survival (OS) = time from date of randomization to date of death due to any cause. For patients not expiring, survival time was censored at the last date they were known to be alive. Patients lacking data beyond randomization had their survival times censored at the date of randomization with a duration of 1 day.</description>
          <population>ITT</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="375"/>
                <count group_id="O2" value="375"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.6" lower_limit="100.1" upper_limit="142.9"/>
                    <measurement group_id="O2" value="94.9" lower_limit="77.7" upper_limit="117.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Unstratified analysis: Hazard Ratio (SU011248 vs IFN—α).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0510</p_value>
            <p_value_desc>p—value is from 2—sided, unstratified tests.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.8209</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6730</ci_lower_limit>
            <ci_upper_limit>1.0013</ci_upper_limit>
            <estimate_desc>Assuming proportional hazards, a hazard ratio less than 1 indicates a reduction in hazard rate in favor of SU011248; a hazard ratio greater than 1 indicates a reduction in hazard rate in favor of IFN—a</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Unstratified analysis: Hazard Ratio (SU011248 vs IFN—α).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0128</p_value>
            <p_value_desc>p-value is from 2—sided, unstratified tests.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.8209</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6730</ci_lower_limit>
            <ci_upper_limit>1.0013</ci_upper_limit>
            <estimate_desc>Assuming proportional hazards, a hazard ratio less than 1 indicates a reduction in hazard rate in favor of SU011248; a hazard ratio greater than 1 indicates a reduction in hazard rate in favor of IFN—a.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified analysis: Hazard Ratio (SU011248 vs IFN—α).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0490</p_value>
            <p_value_desc>p—value is from 2—sided, stratified tests. Stratification factors were: Lactic Dehydrogenase (LDH) &gt; or &lt;= 1.5 x upper limit of normal, Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, and absence or presence of prior nephrectomy.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.8179</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6692</ci_lower_limit>
            <ci_upper_limit>0.9995</ci_upper_limit>
            <estimate_desc>Assuming proportional hazards, a hazard ratio less than 1 indicates a reduction in hazard rate in favor of SU011248; a hazard ratio greater than 1 indicates a reduction in hazard rate in favor of IFN—a.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Tumor Progression (TTP), Core Radiology Assessment</title>
        <description>TTP = time from randomization to first documentation of objective tumor progression. TTP data were censored on the day following the date of last on treatment (including 28 day follow-up period) tumor assessment documenting absence of progressive disease for subjects who did not have objective tumor progression while on treatment or who were given anti-tumor treatment other than study treatment prior to documentation of objective tumor progression. Subjects with no tumor assessments after randomization had TTP censored on the date of randomization with a duration of 1 day.</description>
        <time_frame>Randomization to first documentation of tumor progression: duration of treatment phase</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>SU011248</title>
            <description>50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered.</description>
          </group>
          <group group_id="O2">
            <title>IFN-α</title>
            <description>Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Tumor Progression (TTP), Core Radiology Assessment</title>
          <description>TTP = time from randomization to first documentation of objective tumor progression. TTP data were censored on the day following the date of last on treatment (including 28 day follow-up period) tumor assessment documenting absence of progressive disease for subjects who did not have objective tumor progression while on treatment or who were given anti-tumor treatment other than study treatment prior to documentation of objective tumor progression. Subjects with no tumor assessments after randomization had TTP censored on the date of randomization with a duration of 1 day.</description>
          <population>ITT</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="375"/>
                <count group_id="O2" value="375"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.1" lower_limit="46.6" upper_limit="59.1"/>
                    <measurement group_id="O2" value="22.4" lower_limit="21.9" upper_limit="31.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Unstratified Analysis: Hazard Ratio (SU011248 vs IFN—a)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>p—value is from 2—sided, unstratified test.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.5332</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4345</ci_lower_limit>
            <ci_upper_limit>0.6544</ci_upper_limit>
            <estimate_desc>Assuming proportional hazards, a hazard ratio less than 1 indicates a reduction in hazard rate in favor of SU011248; a hazard ratio greater than 1 indicates a reduction in hazard rate in favor of IFN—a</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified Analysis: Hazard Ratio (SU011248 vs IFN—a)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.00001</p_value>
            <p_value_desc>p—value is from 2—sided, stratified test. Stratification factors are: Lactic Dehydrogenase (LDH) &gt; or &lt;= 1.5 x upper limit of normal, Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, and absence or presence of prior nephrectomy.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.5160</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4191</ci_lower_limit>
            <ci_upper_limit>0.6352</ci_upper_limit>
            <estimate_desc>Assuming proportional hazards, a hazard ratio less than 1 indicates a reduction in hazard rate in favor of SU011248; a hazard ratio greater than 1 indicates a reduction in hazard rate in favor of IFN—a.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Tumor Progression (TTP), Investigator's Assessment</title>
        <description>TTP = time from randomization to first documentation of objective tumor progression. TTP data were censored on the day following the date of last on treatment (including 28 day follow-up period) tumor assessment documenting absence of progressive disease for subjects who did not have objective tumor progression while on treatment or who were given anti-tumor treatment other than the study treatment prior to documentation of objective tumor progression. Subjects with no tumor assessments after randomization had TTP censored on the date of randomization with a duration of 1 day.</description>
        <time_frame>Randomization to first documentation of tumor progression: duration of treatment phase</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>SU011248</title>
            <description>50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered.</description>
          </group>
          <group group_id="O2">
            <title>IFN-α</title>
            <description>Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Tumor Progression (TTP), Investigator's Assessment</title>
          <description>TTP = time from randomization to first documentation of objective tumor progression. TTP data were censored on the day following the date of last on treatment (including 28 day follow-up period) tumor assessment documenting absence of progressive disease for subjects who did not have objective tumor progression while on treatment or who were given anti-tumor treatment other than the study treatment prior to documentation of objective tumor progression. Subjects with no tumor assessments after randomization had TTP censored on the date of randomization with a duration of 1 day.</description>
          <population>ITT</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="375"/>
                <count group_id="O2" value="375"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.0" lower_limit="46.4" upper_limit="59.1"/>
                    <measurement group_id="O2" value="22.3" lower_limit="17.3" upper_limit="31.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Unstratified Analysis: Hazard Ratio (SU011248 vs IFN—α)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>p—value is from 2—sided, unstratified test.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.5454</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4558</ci_lower_limit>
            <ci_upper_limit>0.6526</ci_upper_limit>
            <estimate_desc>Assuming proportional hazards, a hazard ratio &lt; 1 indicates a reduction in hazard rate in favor of SU011248; a hazard ratio &gt; 1 indicates a reduction in hazard rate in favor of IFN—a.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified Analysis: Hazard Ratio (SU011248 vs IFN—α)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.00001</p_value>
            <p_value_desc>p—value is from 2—sided, stratified test. Stratification factors were: Lactic Dehydrogenase (LDH) &gt; or &lt;= 1.5 x upper limit of normal, Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, and absence or presence of prior nephrectomy.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.5417</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4519</ci_lower_limit>
            <ci_upper_limit>0.6492</ci_upper_limit>
            <estimate_desc>Assuming proportional hazards, a hazard ratio less than 1 indicates a reduction in hazard rate in favor of SU011248; a hazard ratio greater than 1 indicates a reduction in hazard rate in favor of IFN—a.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DR), Core Radiology Assessement</title>
        <description>Duration of response (DR) = time from the first documentation of objective tumor response to the first documentation of objective tumor progression or to death due to any cause. DR data were censored on the day following the date of the last on treatment (including 28 day follow-up period) tumor assessment documenting absence of progressive disease for subjects without objective tumor progression who did not die due to any cause while on treatment or who were given anti-tumor treatment other than study treatment prior to observing tumor progression.</description>
        <time_frame>Day 28 of each cycle: duraton of treatment phase</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>SU011248</title>
            <description>50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered.</description>
          </group>
          <group group_id="O2">
            <title>IFN-α</title>
            <description>Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DR), Core Radiology Assessement</title>
          <description>Duration of response (DR) = time from the first documentation of objective tumor response to the first documentation of objective tumor progression or to death due to any cause. DR data were censored on the day following the date of the last on treatment (including 28 day follow-up period) tumor assessment documenting absence of progressive disease for subjects without objective tumor progression who did not die due to any cause while on treatment or who were given anti-tumor treatment other than study treatment prior to observing tumor progression.</description>
          <population>ITT</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.9" lower_limit="46.1" upper_limit="60.1"/>
                    <measurement group_id="O2" value="64.9" lower_limit="41.9" upper_limit="82.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DR), Investigator's Assessment</title>
        <description>Duration of response (DR) = time from the first documentation of objective tumor response to the first documentaion of objective tumor progression or to death due to any cause. DR data were censored on the day following the date of the last on treatment (including 28 day follow-up period) tumor assessment documenting absence of progressive disease for subjects without objective tumor progression who did not die due to any cause while on treatment or who were given anti-tumor treatment other than study treatment prior to observing tumor progression.</description>
        <time_frame>Day 28 of each cycle: duration of treatment phase</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>SU011248</title>
            <description>50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered.</description>
          </group>
          <group group_id="O2">
            <title>IFN-α</title>
            <description>Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DR), Investigator's Assessment</title>
          <description>Duration of response (DR) = time from the first documentation of objective tumor response to the first documentaion of objective tumor progression or to death due to any cause. DR data were censored on the day following the date of the last on treatment (including 28 day follow-up period) tumor assessment documenting absence of progressive disease for subjects without objective tumor progression who did not die due to any cause while on treatment or who were given anti-tumor treatment other than study treatment prior to observing tumor progression.</description>
          <population>ITT</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.3" lower_limit="48.4" upper_limit="64.9"/>
                    <measurement group_id="O2" value="48.1" lower_limit="42.1" upper_limit="120.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FACT-Kidney Symptom Index-Disease Related Symptoms (FKSI-DRS) Subscale</title>
        <description>FACT-Kidney Symptom Index-Disease Related Symptoms (FKSI-DRS) subscale of the FKSI to measure advanced kidney cancer disease related symptoms. Includes 9 items: lack of energy, pain, losing weight, bone pain, fatigue, short of breath, coughing, bothered by fevers, and hematuria. Each question was answered on a five-point Likert-type scale ranging from 0 (not at all) to 4 (very much). Score = the sum score of the item scores in the subscale; total range: 0 to 36. A score greater than 0 indicates the difference favored sunitinib.</description>
        <time_frame>Day 1 &amp; 28 of each cycle: duration of treatment phase</time_frame>
        <population>ITT; summary of FKSI-DRS questionnaire results by treatment; N=number of subjects with evaluable data; n = number of subjects with evaluable data at observation, SU011248 and INF-α treatment groups, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>SU011248</title>
            <description>50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered.</description>
          </group>
          <group group_id="O2">
            <title>IFN-α</title>
            <description>Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>FACT-Kidney Symptom Index-Disease Related Symptoms (FKSI-DRS) Subscale</title>
          <description>FACT-Kidney Symptom Index-Disease Related Symptoms (FKSI-DRS) subscale of the FKSI to measure advanced kidney cancer disease related symptoms. Includes 9 items: lack of energy, pain, losing weight, bone pain, fatigue, short of breath, coughing, bothered by fevers, and hematuria. Each question was answered on a five-point Likert-type scale ranging from 0 (not at all) to 4 (very much). Score = the sum score of the item scores in the subscale; total range: 0 to 36. A score greater than 0 indicates the difference favored sunitinib.</description>
          <population>ITT; summary of FKSI-DRS questionnaire results by treatment; N=number of subjects with evaluable data; n = number of subjects with evaluable data at observation, SU011248 and INF-α treatment groups, respectively.</population>
          <units>scores on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="375"/>
                <count group_id="O2" value="375"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=368, 351)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.74" spread="5.244"/>
                    <measurement group_id="O2" value="29.55" spread="5.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 28 (n=348, 317)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.73" spread="5.080" lower_limit="29.000" upper_limit="29.663"/>
                    <measurement group_id="O2" value="26.68" spread="5.195" lower_limit="27.011" upper_limit="27.782"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 1 (n=327, 246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.66" spread="4.778" lower_limit="29.019" upper_limit="29.667"/>
                    <measurement group_id="O2" value="27.59" spread="4.908" lower_limit="27.016" upper_limit="27.775"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 28 (n= 315, 237)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.49" spread="4.748" lower_limit="29.051" upper_limit="29.677"/>
                    <measurement group_id="O2" value="27.22" spread="4.988" lower_limit="27.019" upper_limit="27.769"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 Day 1 (n=294, 198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.93" spread="4.679" lower_limit="29.068" upper_limit="29.684"/>
                    <measurement group_id="O2" value="28.20" spread="4.452" lower_limit="27.017" upper_limit="27.770"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 Day 28 (n=285, 195)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.72" spread="4.756" lower_limit="29.095" upper_limit="29.698"/>
                    <measurement group_id="O2" value="27.81" spread="5.040" lower_limit="27.006" upper_limit="27.778"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 1 (n=272, 151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.25" spread="4.498"/>
                    <measurement group_id="O2" value="28.85" spread="4.821"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 28 (n=264, 142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.43" spread="4.389"/>
                    <measurement group_id="O2" value="28.30" spread="5.071"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 Day 1 (n=248, 119 )</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.87" spread="3.948"/>
                    <measurement group_id="O2" value="28.57" spread="4.925"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 Day 28 (n=242, 109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.43" spread="4.280"/>
                    <measurement group_id="O2" value="28.37" spread="4.726"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 Day 1 (n=240, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.80" spread="4.214"/>
                    <measurement group_id="O2" value="29.12" spread="4.428"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 Day 28 (n=223, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.62" spread="4.288"/>
                    <measurement group_id="O2" value="28.44" spread="4.957"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 Day 1 (n=208, 79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.93" spread="4.002"/>
                    <measurement group_id="O2" value="28.99" spread="4.974"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 Day 28 (n=203, 75 )</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.73" spread="4.417"/>
                    <measurement group_id="O2" value="28.50" spread="4.556"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8 Day 1 (n=192, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.03" spread="3.649"/>
                    <measurement group_id="O2" value="28.76" spread="4.847"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8 Day 28 (n=190, 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.76" spread="4.096"/>
                    <measurement group_id="O2" value="28.67" spread="4.491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 9 Day 1 (n=172, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.24" spread="3.560"/>
                    <measurement group_id="O2" value="29.86" spread="4.247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 9 Day 28 (n=166, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.72" spread="4.245"/>
                    <measurement group_id="O2" value="29.36" spread="4.418"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 Day 1 (n=161, 50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.73" spread="3.820"/>
                    <measurement group_id="O2" value="29.43" spread="4.455"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 Day 28 (n=155, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.78" spread="4.034"/>
                    <measurement group_id="O2" value="29.03" spread="4.980"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 11 Day 1 (n=138, 35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.72" spread="4.018"/>
                    <measurement group_id="O2" value="29.89" spread="4.006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 11 Day 28 (n=141, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.34" spread="4.117"/>
                    <measurement group_id="O2" value="29.24" spread="5.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 12 Day 1 (n=132, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.76" spread="4.108"/>
                    <measurement group_id="O2" value="29.54" spread="5.607"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 12 Day 28 (n=128, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.63" spread="4.362"/>
                    <measurement group_id="O2" value="29.48" spread="4.774"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 Day 1 (113, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.58" spread="4.354"/>
                    <measurement group_id="O2" value="29.81" spread="4.923"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 Day 28 (n=114, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.30" spread="4.424"/>
                    <measurement group_id="O2" value="29.63" spread="4.550"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 14 Day 1 (n=114, 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.58" spread="4.179"/>
                    <measurement group_id="O2" value="29.35" spread="4.664"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 14 Day 28 (n=105, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.94" spread="4.771"/>
                    <measurement group_id="O2" value="29.23" spread="5.502"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 15 Day 1 (n=100, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.87" spread="4.075"/>
                    <measurement group_id="O2" value="29.18" spread="5.917"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 15 Day 28 (n=94, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.26" spread="4.320"/>
                    <measurement group_id="O2" value="28.89" spread="5.676"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 Day 1 (n=96, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.63" spread="3.786"/>
                    <measurement group_id="O2" value="27.79" spread="5.760"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 Day 28 (n=90, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.51" spread="4.302"/>
                    <measurement group_id="O2" value="28.28" spread="6.267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 17 Day 1 (n=85, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.69" spread="4.132"/>
                    <measurement group_id="O2" value="29.26" spread="5.434"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 17 Day 28 (n=81, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.73" spread="4.155"/>
                    <measurement group_id="O2" value="27.94" spread="7.519"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 18 Day 1 (n=80, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.24" spread="4.091"/>
                    <measurement group_id="O2" value="28.83" spread="7.209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 18 Day 28 (n=70, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.15" spread="4.358"/>
                    <measurement group_id="O2" value="28.73" spread="6.973"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 19 Day 1 (n=71, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.11" spread="4.528"/>
                    <measurement group_id="O2" value="29.64" spread="7.061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 19 Day 28 (n=61, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.48" spread="4.678"/>
                    <measurement group_id="O2" value="28.65" spread="8.131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 20 Day 1 (n=65, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.07" spread="4.073"/>
                    <measurement group_id="O2" value="28.44" spread="8.048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 20 Day 28 (n=53, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.44" spread="4.210"/>
                    <measurement group_id="O2" value="29.22" spread="7.694"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 1 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-Kidney Symptom Index-Disease Related Symptoms (FKSI—DRS) baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.913</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.376</ci_lower_limit>
            <ci_upper_limit>2.450</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 1 Day 28: Difference in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FKSI—DRS baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.935</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.421</ci_lower_limit>
            <ci_upper_limit>2.449</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 2 Day 1: Difference in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FKSI—DRS baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.948</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.443</ci_lower_limit>
            <ci_upper_limit>2.452</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 2 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FKSI—DRS baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.970</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.476</ci_lower_limit>
            <ci_upper_limit>2.464</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 3 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FKSI—DRS baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.983</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.491</ci_lower_limit>
            <ci_upper_limit>2.475</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 3 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FKSI—DRS baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.005</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.510</ci_lower_limit>
            <ci_upper_limit>2.501</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 4 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FKSI—DRS baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.018</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.517</ci_lower_limit>
            <ci_upper_limit>2.519</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 4 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FKSI—DRS baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.040</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.522</ci_lower_limit>
            <ci_upper_limit>2.559</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 5 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FKSI—DRS baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.053</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.522</ci_lower_limit>
            <ci_upper_limit>2.584</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 5 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FKSI—DRS baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.075</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.515</ci_lower_limit>
            <ci_upper_limit>2.635</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 6 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FKSI—DRS baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.088</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.509</ci_lower_limit>
            <ci_upper_limit>2.667</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 6 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FKSI—DRS baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.110</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.494</ci_lower_limit>
            <ci_upper_limit>2.727</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 7 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FKSI—DRS baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.123</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.483</ci_lower_limit>
            <ci_upper_limit>2.763</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 7 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FKSI—DRS baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.146</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.461</ci_lower_limit>
            <ci_upper_limit>2.830</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 8 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FKSI—DRS baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>2.158</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.447</ci_lower_limit>
            <ci_upper_limit>2.869</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 8 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FKSI—DRS baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.181</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.420</ci_lower_limit>
            <ci_upper_limit>2.941</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 9 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FKSI—DRS baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.193</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.404</ci_lower_limit>
            <ci_upper_limit>2.983</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 9 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FKSI—DRS baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.216</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.373</ci_lower_limit>
            <ci_upper_limit>3.059</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 10 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FKSI—DRS baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.228</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.355</ci_lower_limit>
            <ci_upper_limit>3.102</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 10 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FKSI—DRS baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.251</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.321</ci_lower_limit>
            <ci_upper_limit>3.180</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 11 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FKSI—DRS baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.263</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.302</ci_lower_limit>
            <ci_upper_limit>3.225</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 11 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FKSI—DRS baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.286</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.266</ci_lower_limit>
            <ci_upper_limit>3.305</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 12 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FKSI—DRS baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.298</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.246</ci_lower_limit>
            <ci_upper_limit>3.351</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 12 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FKSI—DRS baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.321</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.209</ci_lower_limit>
            <ci_upper_limit>3.433</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 13 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FKSI—DRS baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.333</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.188</ci_lower_limit>
            <ci_upper_limit>3.479</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 13 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FKSI—DRS baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.356</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.150</ci_lower_limit>
            <ci_upper_limit>3.562</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 14 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FKSI—DRS baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.369</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.128</ci_lower_limit>
            <ci_upper_limit>3.609</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 14 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FKSI—DRS baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.391</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.089</ci_lower_limit>
            <ci_upper_limit>3.693</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 15 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FKSI—DRS baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.404</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.067</ci_lower_limit>
            <ci_upper_limit>3.740</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 15 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FKSI—DRS baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0007</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.426</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.027</ci_lower_limit>
            <ci_upper_limit>3.825</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 16 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FKSI—DRS baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0009</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.439</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.005</ci_lower_limit>
            <ci_upper_limit>3.872</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 16 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FKSI—DRS baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0013</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.461</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.964</ci_lower_limit>
            <ci_upper_limit>3.958</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 17 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FKSI—DRS baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0016</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.474</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.942</ci_lower_limit>
            <ci_upper_limit>4.006</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 17 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FKSI—DRS baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0022</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.496</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.901</ci_lower_limit>
            <ci_upper_limit>4.092</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 18 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FKSI—DRS baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0026</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.509</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.878</ci_lower_limit>
            <ci_upper_limit>4.140</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 18 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FKSI—DRS baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0034</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.531</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.836</ci_lower_limit>
            <ci_upper_limit>4.226</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 19 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FKSI—DRS baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0040</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.544</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.813</ci_lower_limit>
            <ci_upper_limit>4.274</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 19 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FKSI—DRS baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0051</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.566</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.772</ci_lower_limit>
            <ci_upper_limit>4.361</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 20 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FKSI—DRS baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0058</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.579</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.748</ci_lower_limit>
            <ci_upper_limit>4.410</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 20 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FKSI—DRS baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0071</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.602</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.706</ci_lower_limit>
            <ci_upper_limit>4.497</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FACT-Kidney Symptom Index (FKSI) Subscale</title>
        <description>FACT-Kidney Symptom Index (FKSI) subscale designed to be a stand-alone instrument to measure symptoms and quality of life in patients with advanced kidney cancer. Contains 15 questions; some questions overlap with the FACT-G questions. Each question was answered on a five-point Likert-type scale ranging from 0 to 4 (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). Total FKSI score = sum score of the 15 item scores; total range: 0 - 60; 0 (most severe symptoms and concerns) to 60 (no symptoms or concerns).</description>
        <time_frame>Day 1 &amp; 28 of each cycle: duration of treatment phase</time_frame>
        <population>ITT; N=number of subjects with evaluable data; n=number of subjects with evaluable data at observation.</population>
        <group_list>
          <group group_id="O1">
            <title>SU011248</title>
            <description>50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered.</description>
          </group>
          <group group_id="O2">
            <title>IFN-α</title>
            <description>Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>FACT-Kidney Symptom Index (FKSI) Subscale</title>
          <description>FACT-Kidney Symptom Index (FKSI) subscale designed to be a stand-alone instrument to measure symptoms and quality of life in patients with advanced kidney cancer. Contains 15 questions; some questions overlap with the FACT-G questions. Each question was answered on a five-point Likert-type scale ranging from 0 to 4 (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). Total FKSI score = sum score of the 15 item scores; total range: 0 - 60; 0 (most severe symptoms and concerns) to 60 (no symptoms or concerns).</description>
          <population>ITT; N=number of subjects with evaluable data; n=number of subjects with evaluable data at observation.</population>
          <units>scores on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="375"/>
                <count group_id="O2" value="375"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=369, 351)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.45" spread="8.464"/>
                    <measurement group_id="O2" value="46.09" spread="8.701"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 28 (n=348, 317)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.71" spread="8.959"/>
                    <measurement group_id="O2" value="40.93" spread="9.292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 1 (n=327, 246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.98" spread="8.401"/>
                    <measurement group_id="O2" value="42.33" spread="8.733"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 28 (n=315, 238)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.75" spread="8.607"/>
                    <measurement group_id="O2" value="42.01" spread="8.659"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 Day 1 (n=294, 198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.60" spread="8.263"/>
                    <measurement group_id="O2" value="43.64" spread="7.983"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 Day 28 (n=285, 195)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.01" spread="8.529"/>
                    <measurement group_id="O2" value="43.13" spread="8.925"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 1 (n=272, 151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.99" spread="8.041"/>
                    <measurement group_id="O2" value="44.78" spread="8.328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 28 (n=264, 142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.08" spread="8.017"/>
                    <measurement group_id="O2" value="44.03" spread="8.913"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 Day 1 (n=248, 119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.99" spread="7.313"/>
                    <measurement group_id="O2" value="44.82" spread="8.293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 Day 28 (n=242, 109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.99" spread="7.768"/>
                    <measurement group_id="O2" value="44.41" spread="8.318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 Day 1 (n=240, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.61" spread="7.860"/>
                    <measurement group_id="O2" value="45.38" spread="7.995"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 Day 28 (n=223, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.40" spread="7.840"/>
                    <measurement group_id="O2" value="44.07" spread="9.003"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 Day 1 (n=208, 79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.84" spread="7.303"/>
                    <measurement group_id="O2" value="45.09" spread="9.061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 Day 28 (n=203, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.39" spread="8.013"/>
                    <measurement group_id="O2" value="44.65" spread="8.082"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8 Day 1 (n=192, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.24" spread="6.818"/>
                    <measurement group_id="O2" value="45.38" spread="8.597"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8 Day 28 (n=190, 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.83" spread="7.589"/>
                    <measurement group_id="O2" value="45.10" spread="8.197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 9 Day 1 (n=172, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.31" spread="6.971"/>
                    <measurement group_id="O2" value="46.88" spread="7.901"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 9 Day 28 (n=166, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.79" spread="7.969"/>
                    <measurement group_id="O2" value="46.16" spread="8.133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 Day 1 (n=161, 50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.90" spread="6.993"/>
                    <measurement group_id="O2" value="46.22" spread="7.778"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 Day 28 (n=155, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.70" spread="7.372"/>
                    <measurement group_id="O2" value="45.16" spread="8.961"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 11 Day 1 (n=138, 35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.90" spread="6.988"/>
                    <measurement group_id="O2" value="46.26" spread="7.398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 11 Day 28 (n=141, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.28" spread="7.330"/>
                    <measurement group_id="O2" value="45.46" spread="8.920"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 12 Day 1 (n=132, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.90" spread="7.458"/>
                    <measurement group_id="O2" value="46.08" spread="9.456"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 12 Day 28 (n=128, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.67" spread="7.696"/>
                    <measurement group_id="O2" value="46.00" spread="8.802"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 Day 1 (n=113, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.02" spread="7.723"/>
                    <measurement group_id="O2" value="46.25" spread="8.833"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 Day 28 (n=114, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.65" spread="7.659"/>
                    <measurement group_id="O2" value="45.84" spread="9.095"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 14 Day 1 (n=114, 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.90" spread="7.370"/>
                    <measurement group_id="O2" value="46.08" spread="8.621"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 14 Day 28 (n=105, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.10" spread="8.641"/>
                    <measurement group_id="O2" value="46.10" spread="9.650"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 15 Day 1 (n=100, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.26" spread="7.663"/>
                    <measurement group_id="O2" value="45.62" spread="9.715"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 15 Day 28 (n=94, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.37" spread="8.040"/>
                    <measurement group_id="O2" value="45.30" spread="9.776"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 Day 1 (n=96, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.75" spread="7.063"/>
                    <measurement group_id="O2" value="43.64" spread="10.688"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 Day 28 (n=90, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.95" spread="7.625"/>
                    <measurement group_id="O2" value="43.46" spread="10.549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 17 Day 1 (n=85, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.07" spread="7.641"/>
                    <measurement group_id="O2" value="45.59" spread="10.302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 17 Day 28 (n=81, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.27" spread="8.016"/>
                    <measurement group_id="O2" value="43.64" spread="11.693"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 18 Day 1 (n=80, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.47" spread="7.598"/>
                    <measurement group_id="O2" value="44.92" spread="12.391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 18 Day 28 (n=70, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.36" spread="7.585"/>
                    <measurement group_id="O2" value="45.27" spread="11.909"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 19 Day 1 (n=71, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.70" spread="7.671"/>
                    <measurement group_id="O2" value="46.64" spread="12.808"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 19 Day 28 (n=61, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.07" spread="8.442"/>
                    <measurement group_id="O2" value="44.47" spread="14.476"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 20 Day 1 (n=65, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.88" spread="7.133"/>
                    <measurement group_id="O2" value="45.00" spread="13.811"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 20 Day 28 (n=53, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.26" spread="8.065"/>
                    <measurement group_id="O2" value="46.00" spread="13.266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 1 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.165</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.234</ci_lower_limit>
            <ci_upper_limit>4.095</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 1 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.205</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.318</ci_lower_limit>
            <ci_upper_limit>4.092</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 2 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.228</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.358</ci_lower_limit>
            <ci_upper_limit>4.097</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 2 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.268</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.418</ci_lower_limit>
            <ci_upper_limit>4.119</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 3 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.291</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.443</ci_lower_limit>
            <ci_upper_limit>4.139</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 3 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.331</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.474</ci_lower_limit>
            <ci_upper_limit>4.189</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 4 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.354</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.484</ci_lower_limit>
            <ci_upper_limit>4.224</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 4 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.395</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.489</ci_lower_limit>
            <ci_upper_limit>4.300</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 5 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.417</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.486</ci_lower_limit>
            <ci_upper_limit>4.348</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 5 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.458</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.469</ci_lower_limit>
            <ci_upper_limit>4.446</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 6 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.480</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.455</ci_lower_limit>
            <ci_upper_limit>4.505</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 6 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.521</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.422</ci_lower_limit>
            <ci_upper_limit>4.620</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 7 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.543</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.399</ci_lower_limit>
            <ci_upper_limit>4.687</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 7 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.584</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.354</ci_lower_limit>
            <ci_upper_limit>4.814</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 8 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.606</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.326</ci_lower_limit>
            <ci_upper_limit>4.887</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 8 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.647</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.272</ci_lower_limit>
            <ci_upper_limit>5.022</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 9 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.669</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.240</ci_lower_limit>
            <ci_upper_limit>5.099</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 9 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.710</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.180</ci_lower_limit>
            <ci_upper_limit>5.240</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 10 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.733</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.145</ci_lower_limit>
            <ci_upper_limit>5.320</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 10 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.773</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.080</ci_lower_limit>
            <ci_upper_limit>5.466</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 11 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.796</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.043</ci_lower_limit>
            <ci_upper_limit>5.548</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 11 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.836</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.975</ci_lower_limit>
            <ci_upper_limit>5.698</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 12 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.859</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.936</ci_lower_limit>
            <ci_upper_limit>5.781</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 12 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.899</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.866</ci_lower_limit>
            <ci_upper_limit>5.933</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 13 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.922</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.826</ci_lower_limit>
            <ci_upper_limit>6.018</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 13 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.962</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.753</ci_lower_limit>
            <ci_upper_limit>6.172</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 14 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.985</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.712</ci_lower_limit>
            <ci_upper_limit>6.258</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 14 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0010</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.026</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.638</ci_lower_limit>
            <ci_upper_limit>6.413</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 15 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0012</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.048</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.597</ci_lower_limit>
            <ci_upper_limit>6.500</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 15 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0018</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.089</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.521</ci_lower_limit>
            <ci_upper_limit>6.656</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 16 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0022</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.111</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.479</ci_lower_limit>
            <ci_upper_limit>6.743</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 16 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0031</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.152</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.403</ci_lower_limit>
            <ci_upper_limit>6.901</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 17 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0037</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.174</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.360</ci_lower_limit>
            <ci_upper_limit>6.988</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 17 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0048</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.215</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.283</ci_lower_limit>
            <ci_upper_limit>7.147</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 18 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0056</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.237</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.240</ci_lower_limit>
            <ci_upper_limit>7.235</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 18 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0071</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.278</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.162</ci_lower_limit>
            <ci_upper_limit>7.394</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 19 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0081</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.300</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.119</ci_lower_limit>
            <ci_upper_limit>7.482</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 19 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0099</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.341</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.041</ci_lower_limit>
            <ci_upper_limit>7.642</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 20 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0111</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.364</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.997</ci_lower_limit>
            <ci_upper_limit>7.730</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 20 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-Kidney Symptom Index (FKSI) baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0133</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.404</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.918</ci_lower_limit>
            <ci_upper_limit>7.890</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Progression-Free Survival (PFS), Investigator's Assessment</title>
        <description>Progression-free survival = time from randomization to first documentation of objective tumor progression or to death due to any cause, whichever occured first. PFS = first event date minus the date of randomization + 1). On study included treatment plus 28-day follow-up periods.</description>
        <time_frame>Day 28 of each 6-week cycle: duration of treatment phase</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>SU011248</title>
            <description>50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered.</description>
          </group>
          <group group_id="O2">
            <title>IFN-α</title>
            <description>Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival (PFS), Investigator's Assessment</title>
          <description>Progression-free survival = time from randomization to first documentation of objective tumor progression or to death due to any cause, whichever occured first. PFS = first event date minus the date of randomization + 1). On study included treatment plus 28-day follow-up periods.</description>
          <population>ITT</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="375"/>
                <count group_id="O2" value="375"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.7" lower_limit="46.3" upper_limit="58.1"/>
                    <measurement group_id="O2" value="22.1" lower_limit="16.7" upper_limit="27.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Unstratified analysis: Hazard Ratio (SU011248 vs IFN—α).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>p-value is from 2-sided, unstratified test.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.5404</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4532</ci_lower_limit>
            <ci_upper_limit>0.6444</ci_upper_limit>
            <estimate_desc>Assuming proportional hazards, a hazard ratio less than 1 indicates a reduction in hazard rate in favor of SU011248: a hazard ratio greater than 1 indicates a reduction in favor of IFN—a.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified analysis: Hazard Ratio (SU011248 vs IFN—α).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.00001</p_value>
            <p_value_desc>p-value is from 2-sided, stratified test. Stratification factors are: Lactic Dehydrogenase (LDH) &gt; or &lt;= 1.5 x upper limit of normal, Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, and absence or presence of prior nephrectomy.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.5418</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4536</ci_lower_limit>
            <ci_upper_limit>0.6473</ci_upper_limit>
            <estimate_desc>Assuming proportional hazards, a hazard ratio less than 1 indicates a reduction in hazard rate in favor of SU011248: a hazard ratio greater than 1 indicates a reduction in favor of IFN—a.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Assessment of Cancer Therapy-General (FACT-G)</title>
        <description>Functional Assessment of Cancer Therapy-General (FACT-G): core questionnaire of the Functional Assessment of Chronic Illness Therapy (FACIT) measurement system that has been validated in a variety of cancer populations. 27 questions grouped into 4 domains that measure a patient’s physical, functional, social and family, and emotional well-being. Five-point Likert-type scale ranging from 0 to 4 (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). Score = sum score of item scores in the subscale; total range: 0 to 108 with higher score indicating better quality of life.</description>
        <time_frame>Day 1 &amp; 28 of each cycle: duration of treatment phase</time_frame>
        <population>ITT; N=number of subjects with evaluable data; n=number of subjects with evaluable data at observation.</population>
        <group_list>
          <group group_id="O1">
            <title>SU011248</title>
            <description>50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered.</description>
          </group>
          <group group_id="O2">
            <title>IFN-α</title>
            <description>Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Assessment of Cancer Therapy-General (FACT-G)</title>
          <description>Functional Assessment of Cancer Therapy-General (FACT-G): core questionnaire of the Functional Assessment of Chronic Illness Therapy (FACIT) measurement system that has been validated in a variety of cancer populations. 27 questions grouped into 4 domains that measure a patient’s physical, functional, social and family, and emotional well-being. Five-point Likert-type scale ranging from 0 to 4 (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). Score = sum score of item scores in the subscale; total range: 0 to 108 with higher score indicating better quality of life.</description>
          <population>ITT; N=number of subjects with evaluable data; n=number of subjects with evaluable data at observation.</population>
          <units>scores on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="375"/>
                <count group_id="O2" value="375"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=368, 346)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.30" spread="15.213"/>
                    <measurement group_id="O2" value="81.22" spread="16.030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 28 (n=345, 316)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.75" spread="15.702"/>
                    <measurement group_id="O2" value="74.91" spread="18.374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 1 (n=328, 247)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.88" spread="15.733"/>
                    <measurement group_id="O2" value="77.02" spread="16.670"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 28 (n=314, 237)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.51" spread="16.229"/>
                    <measurement group_id="O2" value="77.05" spread="17.468"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 Day 1 (n=293, 199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.24" spread="16.121"/>
                    <measurement group_id="O2" value="79.35" spread="16.862"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 Day 28 (n=285, 193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.59" spread="16.144"/>
                    <measurement group_id="O2" value="78.42" spread="17.836"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 1 (n=269, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.32" spread="14.723"/>
                    <measurement group_id="O2" value="80.86" spread="16.477"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 28 (n=263, 142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.08" spread="15.147"/>
                    <measurement group_id="O2" value="80.46" spread="17.136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 Day 1 (n=247, 119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.40" spread="14.019"/>
                    <measurement group_id="O2" value="81.96" spread="15.286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 Day 28 (n=240, 106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.23" spread="15.124"/>
                    <measurement group_id="O2" value="80.60" spread="15.527"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 Day 1 (n=238, 98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.90" spread="15.189"/>
                    <measurement group_id="O2" value="81.97" spread="15.918"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 Day 28 (n=222, 97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.54" spread="15.338"/>
                    <measurement group_id="O2" value="79.70" spread="16.686"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 Day 1 (n=206, 78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.01" spread="15.118"/>
                    <measurement group_id="O2" value="80.39" spread="17.811"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 Day 28 (n=200, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.16" spread="16.207"/>
                    <measurement group_id="O2" value="81.06" spread="16.701"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8 Day 1 (n=192, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.83" spread="13.456"/>
                    <measurement group_id="O2" value="81.25" spread="17.179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8 Day 28 (n=189, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.05" spread="14.699"/>
                    <measurement group_id="O2" value="81.31" spread="16.700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 9 Day 1 (n=170, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.81" spread="14.865"/>
                    <measurement group_id="O2" value="84.50" spread="16.174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 9 Day 28 (n=166, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.71" spread="15.276"/>
                    <measurement group_id="O2" value="83.14" spread="17.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 Day 1 (n=158, 49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.32" spread="14.500"/>
                    <measurement group_id="O2" value="84.03" spread="16.559"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 Day 28 (n=150, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.14" spread="15.193"/>
                    <measurement group_id="O2" value="81.79" spread="17.994"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 11 Day 1 (n=134, 35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.75" spread="14.791"/>
                    <measurement group_id="O2" value="81.60" spread="16.729"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 11 Day 28 (n=139, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.91" spread="14.865"/>
                    <measurement group_id="O2" value="80.20" spread="19.213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 12 Day 1 (n=130, 29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.31" spread="15.181"/>
                    <measurement group_id="O2" value="80.99" spread="20.219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 12 Day 28 (n=126, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.43" spread="15.152"/>
                    <measurement group_id="O2" value="81.73" spread="18.745"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 Day 1 (n=113, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.50" spread="15.209"/>
                    <measurement group_id="O2" value="81.18" spread="20.198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 Day 28 (n=114, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.61" spread="14.445"/>
                    <measurement group_id="O2" value="80.67" spread="18.678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 14 Day 1 (n=112, 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.24" spread="14.398"/>
                    <measurement group_id="O2" value="81.22" spread="17.506"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 14 Day 28 (n=107, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.34" spread="16.300"/>
                    <measurement group_id="O2" value="81.57" spread="20.188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 15 Day 1 (n=101, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.24" spread="14.742"/>
                    <measurement group_id="O2" value="81.66" spread="18.326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 15 Day 28 (n=96, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.64" spread="15.722"/>
                    <measurement group_id="O2" value="80.88" spread="18.913"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 Day 1 (n=94, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.77" spread="14.741"/>
                    <measurement group_id="O2" value="78.20" spread="18.994"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 Day 28 (n=89, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.38" spread="15.481"/>
                    <measurement group_id="O2" value="78.38" spread="19.749"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 17 Day 1 (n=84, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.78" spread="14.800"/>
                    <measurement group_id="O2" value="81.80" spread="20.161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 17 Day 28 (n=80, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.42" spread="15.106"/>
                    <measurement group_id="O2" value="78.96" spread="21.571"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 18 Day 1 (n=79, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.74" spread="14.987"/>
                    <measurement group_id="O2" value="82.24" spread="23.763"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 18 Day 28 (n=70, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.51" spread="14.831"/>
                    <measurement group_id="O2" value="82.27" spread="21.950"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 19 Day 1 (n=71, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.16" spread="14.245"/>
                    <measurement group_id="O2" value="82.48" spread="24.198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 19 Day 28 (n=61, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.54" spread="16.679"/>
                    <measurement group_id="O2" value="79.63" spread="27.938"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 20 Day 1 (n=63, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.96" spread="14.441"/>
                    <measurement group_id="O2" value="81.70" spread="27.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 20 Day 28 (n=52, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.62" spread="16.257"/>
                    <measurement group_id="O2" value="79.54" spread="26.109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 1 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline Functional Assessment of Cancer Therapy-General (FACT-G) baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.486</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.852</ci_lower_limit>
            <ci_upper_limit>7.119</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 1 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.535</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.955</ci_lower_limit>
            <ci_upper_limit>7.115</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 2 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.562</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.000</ci_lower_limit>
            <ci_upper_limit>7.124</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 2 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.611</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.061</ci_lower_limit>
            <ci_upper_limit>7.162</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 3 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.639</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.083</ci_lower_limit>
            <ci_upper_limit>7.195</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 3 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.688</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.100</ci_lower_limit>
            <ci_upper_limit>7.276</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 4 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.715</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.098</ci_lower_limit>
            <ci_upper_limit>7.333</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 4 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.764</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.075</ci_lower_limit>
            <ci_upper_limit>7.454</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 5 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.792</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.053</ci_lower_limit>
            <ci_upper_limit>7.531</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 5 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.841</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.998</ci_lower_limit>
            <ci_upper_limit>7.684</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 6 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.868</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.960</ci_lower_limit>
            <ci_upper_limit>7.777</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 6 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.917</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.880</ci_lower_limit>
            <ci_upper_limit>7.955</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 7 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.945</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.830</ci_lower_limit>
            <ci_upper_limit>8.060</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 7 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.994</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.731</ci_lower_limit>
            <ci_upper_limit>8.257</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 8 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.021</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.672</ci_lower_limit>
            <ci_upper_limit>8.370</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 8 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.071</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.560</ci_lower_limit>
            <ci_upper_limit>8.581</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 9 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.098</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.495</ci_lower_limit>
            <ci_upper_limit>8.701</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 9 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.147</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.373</ci_lower_limit>
            <ci_upper_limit>8.921</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 10 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.174</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.303</ci_lower_limit>
            <ci_upper_limit>9.045</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 10 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.224</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.174</ci_lower_limit>
            <ci_upper_limit>9.273</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 11 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.251</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.101</ci_lower_limit>
            <ci_upper_limit>9.401</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 11 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.300</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.966</ci_lower_limit>
            <ci_upper_limit>9.634</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 12 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.327</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.890</ci_lower_limit>
            <ci_upper_limit>9.765</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 12 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.377</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.751</ci_lower_limit>
            <ci_upper_limit>10.002</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 13 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0008</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.404</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.673</ci_lower_limit>
            <ci_upper_limit>10.135</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 13 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0013</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.453</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.530</ci_lower_limit>
            <ci_upper_limit>10.376</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 14 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0016</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.480</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.451</ci_lower_limit>
            <ci_upper_limit>10.510</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 14 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0025</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.530</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.306</ci_lower_limit>
            <ci_upper_limit>10.754</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 15 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0030</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.557</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.224</ci_lower_limit>
            <ci_upper_limit>10.889</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 15 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0043</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.606</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.077</ci_lower_limit>
            <ci_upper_limit>11.135</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 16 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0051</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.634</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.995</ci_lower_limit>
            <ci_upper_limit>11.272</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 16 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0068</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.683</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.847</ci_lower_limit>
            <ci_upper_limit>11.519</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 17 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0079</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.710</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.764</ci_lower_limit>
            <ci_upper_limit>11.657</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 17 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0100</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.759</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.613</ci_lower_limit>
            <ci_upper_limit>11.905</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 18 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0114</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.787</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.530</ci_lower_limit>
            <ci_upper_limit>12.043</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 18 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0141</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.836</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.378</ci_lower_limit>
            <ci_upper_limit>12.293</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 19 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0157</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.863</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.294</ci_lower_limit>
            <ci_upper_limit>12.432</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 19 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0189</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.912</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.142</ci_lower_limit>
            <ci_upper_limit>12.683</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 20 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0208</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.940</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.057</ci_lower_limit>
            <ci_upper_limit>12.822</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 20 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0244</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.989</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.904</ci_lower_limit>
            <ci_upper_limit>13.074</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Assessment of Cancer Therapy-General (FACT-G): Physical Well Being (PWB) Subscale</title>
        <description>Physical well-being (PWB) subscale of the Functional Assessment of Cancer Therapy-General (FACT-G). Each question was answered on a five-point Likert-type scale ranging from 0 to 4 (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). Score = the sum score of the item scores in the subscale; range: 0 to 28; lower score indicates better physical well-being.</description>
        <time_frame>Day 1 &amp; 28 of each cycle: duration of treatment phase</time_frame>
        <population>ITT; N=number of subjects with evaluable data; n=number of subjects with evaluable data at observation.</population>
        <group_list>
          <group group_id="O1">
            <title>SU011248</title>
            <description>50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered.</description>
          </group>
          <group group_id="O2">
            <title>IFN-α</title>
            <description>Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Assessment of Cancer Therapy-General (FACT-G): Physical Well Being (PWB) Subscale</title>
          <description>Physical well-being (PWB) subscale of the Functional Assessment of Cancer Therapy-General (FACT-G). Each question was answered on a five-point Likert-type scale ranging from 0 to 4 (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). Score = the sum score of the item scores in the subscale; range: 0 to 28; lower score indicates better physical well-being.</description>
          <population>ITT; N=number of subjects with evaluable data; n=number of subjects with evaluable data at observation.</population>
          <units>scores on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="375"/>
                <count group_id="O2" value="375"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=369, 348)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.14" spread="5.209"/>
                    <measurement group_id="O2" value="22.70" spread="5.224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 28 (n=348, 318)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.43" spread="6.052"/>
                    <measurement group_id="O2" value="18.85" spread="6.168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 1 (n=329, 247)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.22" spread="5.161"/>
                    <measurement group_id="O2" value="20.05" spread="5.499"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 28 (n=316, 239)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.34" spread="5.654"/>
                    <measurement group_id="O2" value="19.84" spread="5.706"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 Day 1 (n=294, 200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.45" spread="5.123"/>
                    <measurement group_id="O2" value="20.87" spread="5.281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 Day 28 (n=286, 195)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.18" spread="5.650"/>
                    <measurement group_id="O2" value="20.63" spread="5.395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 1 (n=270, 150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.72" spread="4.641"/>
                    <measurement group_id="O2" value="21.56" spread="4.581"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 28 (n=264, 142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.00" spread="5.120"/>
                    <measurement group_id="O2" value="21.31" spread="5.110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 Day 1 (n=248, 120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.24" spread="4.143"/>
                    <measurement group_id="O2" value="21.84" spread="4.567"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 Day 28 (n=241, 106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.91" spread="5.062"/>
                    <measurement group_id="O2" value="21.23" spread="4.867"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 Day 1 (n=239, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.99" spread="4.385"/>
                    <measurement group_id="O2" value="21.70" spread="4.761"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 Day 28 (n=224, 97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.22" spread="5.070"/>
                    <measurement group_id="O2" value="20.96" spread="5.384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 Day 1 (n=207, 79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.05" spread="4.414"/>
                    <measurement group_id="O2" value="21.67" spread="4.964"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 Day 28 (n=201, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.22" spread="5.250"/>
                    <measurement group_id="O2" value="21.66" spread="4.595"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8 Day 1 (n=193, 67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.58" spread="3.715"/>
                    <measurement group_id="O2" value="21.94" spread="4.870"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8 Day 28 (n=189, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.51" spread="4.666"/>
                    <measurement group_id="O2" value="21.40" spread="4.910"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 9 Day 1 (n=172, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.41" spread="4.071"/>
                    <measurement group_id="O2" value="22.58" spread="4.367"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 9 Day 28 (n=166, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.29" spread="5.068"/>
                    <measurement group_id="O2" value="22.38" spread="4.400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 Day 1 (n=159, 49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.94" spread="4.053"/>
                    <measurement group_id="O2" value="22.60" spread="4.124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 Day 28 (n=151, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.21" spread="4.848"/>
                    <measurement group_id="O2" value="21.83" spread="5.165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 11 Day 1 (n=135, 35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.16" spread="4.069"/>
                    <measurement group_id="O2" value="22.23" spread="4.194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 11 Day 28 (n=140, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.98" spread="4.597"/>
                    <measurement group_id="O2" value="21.88" spread="5.173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 12 Day 1 (n=131, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.03" spread="4.291"/>
                    <measurement group_id="O2" value="22.60" spread="5.236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 12 Day 28 (n=127, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.87" spread="4.721"/>
                    <measurement group_id="O2" value="21.90" spread="4.867"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 Day 1 (n=114, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.05" spread="4.281"/>
                    <measurement group_id="O2" value="21.99" spread="5.187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 Day 28 (n=114, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.26" spread="4.623"/>
                    <measurement group_id="O2" value="21.80" spread="5.369"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 14 Day 1 (n=112, 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.02" spread="4.401"/>
                    <measurement group_id="O2" value="22.05" spread="4.906"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 14 Day 28 (n=107, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.80" spread="5.310"/>
                    <measurement group_id="O2" value="22.75" spread="4.875"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 15 Day 1 (n=101, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.26" spread="4.475"/>
                    <measurement group_id="O2" value="22.33" spread="5.173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 15 Day 28 (n=96, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.95" spread="4.978"/>
                    <measurement group_id="O2" value="22.07" spread="4.908"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 Day 1 (n=94, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.60" spread="4.337"/>
                    <measurement group_id="O2" value="20.63" spread="6.125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 Day 28 (n=90, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.31" spread="4.939"/>
                    <measurement group_id="O2" value="21.42" spread="6.194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 17 Day 1 (n=85, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.99" spread="4.513"/>
                    <measurement group_id="O2" value="21.81" spread="5.776"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 17 Day 28 (n=80, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.68" spread="4.653"/>
                    <measurement group_id="O2" value="20.50" spread="6.757"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 18 Day 1 (n=79, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.85" spread="4.388"/>
                    <measurement group_id="O2" value="21.83" spread="6.672"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 18 Day 28 (n=70, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.89" spread="5.006"/>
                    <measurement group_id="O2" value="22.45" spread="5.610"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 19 Day 1 (n=71, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.20" spread="4.426"/>
                    <measurement group_id="O2" value="22.45" spread="6.773"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 19 Day 28 (n=61, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.82" spread="4.696"/>
                    <measurement group_id="O2" value="21.60" spread="7.457"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 20 Day 1 (n=63, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.68" spread="4.204"/>
                    <measurement group_id="O2" value="21.78" spread="7.311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 20 Day 28 (n=52, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.81" spread="4.835"/>
                    <measurement group_id="O2" value="22.33" spread="6.423"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 1 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline Functional Assessment of Cancer Therapy-General (FACT-G) Physical Well Being (PWB) subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.459</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.805</ci_lower_limit>
            <ci_upper_limit>2.114</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 1 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.453</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.827</ci_lower_limit>
            <ci_upper_limit>2.079</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 2 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.450</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.837</ci_lower_limit>
            <ci_upper_limit>2.063</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 2 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.444</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.847</ci_lower_limit>
            <ci_upper_limit>2.041</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 3 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.440</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.848</ci_lower_limit>
            <ci_upper_limit>2.032</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 3 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.434</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.844</ci_lower_limit>
            <ci_upper_limit>2.024</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 4 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.431</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.838</ci_lower_limit>
            <ci_upper_limit>2.023</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 4 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.424</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.819</ci_lower_limit>
            <ci_upper_limit>2.029</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 5 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.421</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.805</ci_lower_limit>
            <ci_upper_limit>2.037</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 5 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.415</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.774</ci_lower_limit>
            <ci_upper_limit>2.056</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 6 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.411</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.753</ci_lower_limit>
            <ci_upper_limit>2.069</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 6 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.405</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.711</ci_lower_limit>
            <ci_upper_limit>2.099</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 7 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.402</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.685</ci_lower_limit>
            <ci_upper_limit>2.119</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 7 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.396</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.634</ci_lower_limit>
            <ci_upper_limit>2.157</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 8 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.392</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.604</ci_lower_limit>
            <ci_upper_limit>2.180</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 8 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0012</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.386</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.547</ci_lower_limit>
            <ci_upper_limit>2.225</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 9 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0018</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.383</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.514</ci_lower_limit>
            <ci_upper_limit>2.252</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 9 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0035</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.376</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.451</ci_lower_limit>
            <ci_upper_limit>2.301</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 10 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0049</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.373</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.416</ci_lower_limit>
            <ci_upper_limit>2.330</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 10 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0084</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.367</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.350</ci_lower_limit>
            <ci_upper_limit>2.383</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 11 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0110</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.363</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.313</ci_lower_limit>
            <ci_upper_limit>2.414</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 11 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0168</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.357</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.245</ci_lower_limit>
            <ci_upper_limit>2.470</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 12 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0208</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.354</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.206</ci_lower_limit>
            <ci_upper_limit>2.501</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 12 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0293</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.348</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.136</ci_lower_limit>
            <ci_upper_limit>2.559</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 13 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0348</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.344</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.096</ci_lower_limit>
            <ci_upper_limit>2.592</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 13 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0459</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.338</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.024</ci_lower_limit>
            <ci_upper_limit>2.652</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 14 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G PWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0528</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.335</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.016</ci_lower_limit>
            <ci_upper_limit>2.685</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 14 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0663</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.328</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.090</ci_lower_limit>
            <ci_upper_limit>2.746</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 15 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0744</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.325</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.131</ci_lower_limit>
            <ci_upper_limit>2.780</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 15 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0898</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.319</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.205</ci_lower_limit>
            <ci_upper_limit>2.842</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 16 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0988</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.315</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.246</ci_lower_limit>
            <ci_upper_limit>2.877</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 16 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1156</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.309</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.321</ci_lower_limit>
            <ci_upper_limit>2.940</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 17 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1252</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.306</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.363</ci_lower_limit>
            <ci_upper_limit>2.975</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 17 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1429</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.300</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.439</ci_lower_limit>
            <ci_upper_limit>3.038</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 18 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1529</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.296</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.481</ci_lower_limit>
            <ci_upper_limit>3.074</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 18 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1711</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.290</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.558</ci_lower_limit>
            <ci_upper_limit>3.138</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 19 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1813</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.287</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.600</ci_lower_limit>
            <ci_upper_limit>3.173</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 19 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1998</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.280</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.677</ci_lower_limit>
            <ci_upper_limit>3.238</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 20 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2100</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.277</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.720</ci_lower_limit>
            <ci_upper_limit>3.273</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 20 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G PWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2283</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.271</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.797</ci_lower_limit>
            <ci_upper_limit>3.338</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Assessment of Cancer Therapy-General (FACT-G): Social/Family Well Being (SWB) Subscale</title>
        <description>Social/family well-being (SWB)subscale of the Functional Assessment of Cancer Therapy-General (FACT-G). Each question was answered on a five-point Likert-type scale ranging from 0 to 4 (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). Score = the sum score of the item scores in the subscale; range: 0 to 28; lower score indicates less social/family well-being.</description>
        <time_frame>Day 1 &amp; 28 of each cycle: duration of treatment phase</time_frame>
        <population>ITT; N=number of subjects with evaluable data; n=number of subjects with evaluable data at observation.</population>
        <group_list>
          <group group_id="O1">
            <title>SU011248</title>
            <description>50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered.</description>
          </group>
          <group group_id="O2">
            <title>IFN-α</title>
            <description>Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Assessment of Cancer Therapy-General (FACT-G): Social/Family Well Being (SWB) Subscale</title>
          <description>Social/family well-being (SWB)subscale of the Functional Assessment of Cancer Therapy-General (FACT-G). Each question was answered on a five-point Likert-type scale ranging from 0 to 4 (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). Score = the sum score of the item scores in the subscale; range: 0 to 28; lower score indicates less social/family well-being.</description>
          <population>ITT; N=number of subjects with evaluable data; n=number of subjects with evaluable data at observation.</population>
          <units>scores on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="375"/>
                <count group_id="O2" value="375"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=370, 349)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.14" spread="4.641"/>
                    <measurement group_id="O2" value="22.94" spread="4.735"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 28 (n=348, 319)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.60" spread="4.088"/>
                    <measurement group_id="O2" value="22.20" spread="5.076"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 1 (n=328, 247)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.50" spread="4.344"/>
                    <measurement group_id="O2" value="22.31" spread="5.190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 28 (n=315, 238)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.40" spread="4.471"/>
                    <measurement group_id="O2" value="22.22" spread="5.203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 Day 1 (n=292, 200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.51" spread="4.375"/>
                    <measurement group_id="O2" value="22.42" spread="5.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 Day 28 (n=284, 194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.44" spread="4.369"/>
                    <measurement group_id="O2" value="22.12" spread="5.289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 1 (n=269, 150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.73" spread="4.072"/>
                    <measurement group_id="O2" value="22.26" spread="5.275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 28 (n=263, 142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.36" spread="4.451"/>
                    <measurement group_id="O2" value="22.38" spread="5.198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 Day 1 (n=247, 120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.53" spread="4.334"/>
                    <measurement group_id="O2" value="22.35" spread="5.486"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 Day 28 (n=241, 107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.68" spread="4.137"/>
                    <measurement group_id="O2" value="22.36" spread="4.956"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 Day 1 (n=238, 98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.35" spread="4.428"/>
                    <measurement group_id="O2" value="22.56" spread="4.678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 Day 28 (n=224, 97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.40" spread="4.393"/>
                    <measurement group_id="O2" value="22.33" spread="4.641"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 Day 1 (n=207, 79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.29" spread="4.532"/>
                    <measurement group_id="O2" value="22.46" spread="4.722"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 Day 28 (n=200, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.13" spread="4.585"/>
                    <measurement group_id="O2" value="22.10" spread="5.286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8 Day 1 (n=193, 67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.67" spread="4.225"/>
                    <measurement group_id="O2" value="21.95" spread="5.112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8 Day 28 (n=189, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.26" spread="4.402"/>
                    <measurement group_id="O2" value="22.17" spread="5.236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 9 Day 1 (n=172, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.26" spread="4.376"/>
                    <measurement group_id="O2" value="22.74" spread="4.826"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 9 Day 28 (n=166, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.26" spread="4.395"/>
                    <measurement group_id="O2" value="21.96" spread="5.418"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 Day 1 (n=158, 49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.08" spread="4.348"/>
                    <measurement group_id="O2" value="22.45" spread="5.279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 Day 28 (n=151, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.03" spread="4.417"/>
                    <measurement group_id="O2" value="22.06" spread="5.065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 11 Day 1 (n=135, 35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.05" spread="4.521"/>
                    <measurement group_id="O2" value="21.51" spread="5.267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 11 Day 28 (n=140, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.71" spread="4.624"/>
                    <measurement group_id="O2" value="21.09" spread="5.957"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 12 Day 1 (n=131, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.23" spread="4.563"/>
                    <measurement group_id="O2" value="20.79" spread="6.007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 12 Day 28 (n=127, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.07" spread="4.586"/>
                    <measurement group_id="O2" value="21.25" spread="5.627"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 Day 1 (n=114, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.15" spread="4.498"/>
                    <measurement group_id="O2" value="20.93" spread="6.142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 Day 28 (n=114, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.31" spread="4.255"/>
                    <measurement group_id="O2" value="21.30" spread="5.491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 14 Day 1 (n=112, 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.82" spread="4.647"/>
                    <measurement group_id="O2" value="21.51" spread="5.510"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 14 Day 28 (n=107, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.24" spread="4.503"/>
                    <measurement group_id="O2" value="20.32" spread="6.628"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 15 Day 1 (n=101, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.28" spread="4.178"/>
                    <measurement group_id="O2" value="20.35" spread="5.986"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 15 Day 28 (n=96, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.04" spread="4.312"/>
                    <measurement group_id="O2" value="20.23" spread="6.162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 Day 1 (n=94, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.11" spread="4.335"/>
                    <measurement group_id="O2" value="21.41" spread="5.196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 Day 28 (n=89, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.41" spread="4.322"/>
                    <measurement group_id="O2" value="21.52" spread="5.821"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 17 Day 1 (n=85, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.42" spread="4.603"/>
                    <measurement group_id="O2" value="22.25" spread="5.037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 17 Day 28 (n=80, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.50" spread="4.424"/>
                    <measurement group_id="O2" value="21.75" spread="5.680"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 18 Day 1 (n=79, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.53" spread="4.428"/>
                    <measurement group_id="O2" value="21.71" spread="6.276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 18 Day 28 (n=70, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.70" spread="4.410"/>
                    <measurement group_id="O2" value="21.27" spread="6.051"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 19 Day 1 (n=71, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.85" spread="4.270"/>
                    <measurement group_id="O2" value="21.30" spread="5.894"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 19 Day 28 (n=61, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.53" spread="4.641"/>
                    <measurement group_id="O2" value="20.73" spread="6.816"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 20 Day 1 (n=63, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.60" spread="4.045"/>
                    <measurement group_id="O2" value="21.26" spread="7.201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 20 Day 28 (n=52, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.93" spread="4.898"/>
                    <measurement group_id="O2" value="20.67" spread="6.251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 1 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline Functional Assessment of Cancer Therapy-General (FACT-G) Social/Family Well Being (SWB) subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.214</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.719</ci_lower_limit>
            <ci_upper_limit>1.708</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 1 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.216</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.729</ci_lower_limit>
            <ci_upper_limit>1.703</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 2 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.217</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.731</ci_lower_limit>
            <ci_upper_limit>1.704</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 2 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.220</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.730</ci_lower_limit>
            <ci_upper_limit>1.710</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 3 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.221</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.727</ci_lower_limit>
            <ci_upper_limit>1.716</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 3 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.224</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.716</ci_lower_limit>
            <ci_upper_limit>1.732</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 4 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.225</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.707</ci_lower_limit>
            <ci_upper_limit>1.744</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 4 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.228</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.687</ci_lower_limit>
            <ci_upper_limit>1.769</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 5 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.229</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.673</ci_lower_limit>
            <ci_upper_limit>1.785</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 5 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.232</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.646</ci_lower_limit>
            <ci_upper_limit>1.818</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 6 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.233</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.629</ci_lower_limit>
            <ci_upper_limit>1.838</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 6 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.236</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.595</ci_lower_limit>
            <ci_upper_limit>1.876</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 7 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.237</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.575</ci_lower_limit>
            <ci_upper_limit>1.899</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 7 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.240</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.537</ci_lower_limit>
            <ci_upper_limit>1.942</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 8 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0008</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.241</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.515</ci_lower_limit>
            <ci_upper_limit>1.967</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 8 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0015</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.244</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.474</ci_lower_limit>
            <ci_upper_limit>2.013</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 9 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0021</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.245</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.450</ci_lower_limit>
            <ci_upper_limit>2.040</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 9 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0037</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.248</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.406</ci_lower_limit>
            <ci_upper_limit>2.089</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 10 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0048</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.249</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.382</ci_lower_limit>
            <ci_upper_limit>2.116</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 10 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0074</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.251</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.336</ci_lower_limit>
            <ci_upper_limit>2.167</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 11 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0092</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.253</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.310</ci_lower_limit>
            <ci_upper_limit>2.196</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 11 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0132</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.255</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.262</ci_lower_limit>
            <ci_upper_limit>2.248</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 12 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0159</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.257</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.236</ci_lower_limit>
            <ci_upper_limit>2.278</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 12 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0213</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.259</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.187</ci_lower_limit>
            <ci_upper_limit>2.332</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 13 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0248</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.261</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.160</ci_lower_limit>
            <ci_upper_limit>2.362</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 13 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0318</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.263</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.110</ci_lower_limit>
            <ci_upper_limit>2.416</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 14 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0360</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.265</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.083</ci_lower_limit>
            <ci_upper_limit>2.447</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 14 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0443</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.267</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.032</ci_lower_limit>
            <ci_upper_limit>2.502</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 15 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0493</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.269</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.004</ci_lower_limit>
            <ci_upper_limit>2.533</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 15 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0587</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.271</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.047</ci_lower_limit>
            <ci_upper_limit>2.589</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 16 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0642</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.273</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.075</ci_lower_limit>
            <ci_upper_limit>2.620</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 16 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0746</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.275</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.127</ci_lower_limit>
            <ci_upper_limit>2.677</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 17 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0806</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.276</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.155</ci_lower_limit>
            <ci_upper_limit>2.708</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 17 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0917</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.279</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.207</ci_lower_limit>
            <ci_upper_limit>2.765</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 18 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0980</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.280</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.236</ci_lower_limit>
            <ci_upper_limit>2.797</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 18 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1095</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.283</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.288</ci_lower_limit>
            <ci_upper_limit>2.854</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 19 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1161</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.284</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.318</ci_lower_limit>
            <ci_upper_limit>2.886</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 19 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1280</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.287</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.370</ci_lower_limit>
            <ci_upper_limit>2.944</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 20 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1346</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.288</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.399</ci_lower_limit>
            <ci_upper_limit>2.976</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 20 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT-G SWB subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1466</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.291</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.452</ci_lower_limit>
            <ci_upper_limit>3.034</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Assessment of Cancer Therapy-General (FACT-G): Emotional Well Being (EWB) Subscale</title>
        <description>Emotional well-being (EWB)subscale of the Functional Assessment of Cancer Therapy-General (FACT-G). Each question was answered on a five-point Likert-type scale ranging from 0 to 4 (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). Score = the sum score of the item scores in the subscale; range: 0 to 24; lower score indicates better emotional well-being.</description>
        <time_frame>Day 1 &amp; 28 of each cycle: duration of treatment phase</time_frame>
        <population>ITT; N=number of subjects with evaluable data; n=number of subjects with evaluable data at observation.</population>
        <group_list>
          <group group_id="O1">
            <title>SU011248</title>
            <description>50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered.</description>
          </group>
          <group group_id="O2">
            <title>IFN-α</title>
            <description>Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Assessment of Cancer Therapy-General (FACT-G): Emotional Well Being (EWB) Subscale</title>
          <description>Emotional well-being (EWB)subscale of the Functional Assessment of Cancer Therapy-General (FACT-G). Each question was answered on a five-point Likert-type scale ranging from 0 to 4 (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). Score = the sum score of the item scores in the subscale; range: 0 to 24; lower score indicates better emotional well-being.</description>
          <population>ITT; N=number of subjects with evaluable data; n=number of subjects with evaluable data at observation.</population>
          <units>scores on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="375"/>
                <count group_id="O2" value="375"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (370, 352)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.15" spread="4.548"/>
                    <measurement group_id="O2" value="17.06" spread="4.609"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 28 (n=347, 318)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.76" spread="4.347"/>
                    <measurement group_id="O2" value="17.40" spread="5.123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 1 (n=328, 249)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.46" spread="4.218"/>
                    <measurement group_id="O2" value="17.52" spread="4.560"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 28 (n=316, 237)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.46" spread="4.342"/>
                    <measurement group_id="O2" value="17.73" spread="4.637"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 Day 1 (n=294, 200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.82" spread="4.236"/>
                    <measurement group_id="O2" value="18.13" spread="4.603"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 Day 28 (n=287, 196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.53" spread="4.494"/>
                    <measurement group_id="O2" value="18.17" spread="4.704"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 1 (n=272, 152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.04" spread="4.182"/>
                    <measurement group_id="O2" value="18.80" spread="4.246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 28 (n=265, 142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.76" spread="4.343"/>
                    <measurement group_id="O2" value="18.39" spread="4.378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 Day 1 (n=249, 120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.18" spread="3.903"/>
                    <measurement group_id="O2" value="19.00" spread="4.062"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 Day 28 (n=241, 109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.63" spread="4.298"/>
                    <measurement group_id="O2" value="18.70" spread="4.144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 Day 1 (n=240, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.99" spread="4.154"/>
                    <measurement group_id="O2" value="18.60" spread="4.338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 Day 28 (n=222, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.73" spread="4.311"/>
                    <measurement group_id="O2" value="18.14" spread="4.747"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 Day 1 (n=208, 77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.08" spread="4.324"/>
                    <measurement group_id="O2" value="18.08" spread="5.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 Day 28 (n=204, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.69" spread="4.595"/>
                    <measurement group_id="O2" value="18.55" spread="4.691"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8 Day 1 (n=192, 67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.33" spread="4.104"/>
                    <measurement group_id="O2" value="18.54" spread="4.613"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8 Day 28 (n=189, 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.98" spread="4.026"/>
                    <measurement group_id="O2" value="18.55" spread="4.734"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 9 Day 1 (n=171, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.25" spread="4.341"/>
                    <measurement group_id="O2" value="18.98" spread="4.654"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 9 Day 28 (n=167, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.93" spread="4.376"/>
                    <measurement group_id="O2" value="18.76" spread="4.831"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 Day 1 (n=161, 50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.32" spread="4.191"/>
                    <measurement group_id="O2" value="18.92" spread="4.548"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 Day 28 (n=154, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.71" spread="4.557"/>
                    <measurement group_id="O2" value="18.36" spread="4.778"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 11 Day 1 (n=138, 35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.92" spread="4.514"/>
                    <measurement group_id="O2" value="18.97" spread="4.225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 11 Day 28 (n=141, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.10" spread="4.209"/>
                    <measurement group_id="O2" value="18.52" spread="5.316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 12 Day 1 (n=132, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.14" spread="4.547"/>
                    <measurement group_id="O2" value="18.87" spread="4.547"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 12 Day 28 (n=128, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.06" spread="4.456"/>
                    <measurement group_id="O2" value="19.45" spread="4.178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 Day 1 (n=114, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.38" spread="4.170"/>
                    <measurement group_id="O2" value="18.63" spread="4.853"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 Day 28 (n=114, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.39" spread="4.034"/>
                    <measurement group_id="O2" value="18.97" spread="3.993"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 14 Day 1 (n=114, 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.55" spread="3.951"/>
                    <measurement group_id="O2" value="18.05" spread="4.814"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 14 Day 28 (n=107, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.23" spread="4.522"/>
                    <measurement group_id="O2" value="18.76" spread="4.085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 15 Day 1 (n=101, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.57" spread="4.171"/>
                    <measurement group_id="O2" value="18.24" spread="4.795"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 15 Day 28 (n=96, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.41" spread="4.459"/>
                    <measurement group_id="O2" value="18.75" spread="4.447"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 Day 1 (n=96, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.54" spread="4.258"/>
                    <measurement group_id="O2" value="17.26" spread="5.675"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 Day 28 (n=91, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.33" spread="4.287"/>
                    <measurement group_id="O2" value="16.83" spread="5.113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 17 Day 1 (n=84, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.95" spread="3.997"/>
                    <measurement group_id="O2" value="18.28" spread="5.151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 17 Day 28 (n=81, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.66" spread="4.420"/>
                    <measurement group_id="O2" value="18.00" spread="5.218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 18 Day 1 (n=80, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.64" spread="4.132"/>
                    <measurement group_id="O2" value="19.62" spread="4.971"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 18 Day 28 (n=71, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.34" spread="4.125"/>
                    <measurement group_id="O2" value="19.55" spread="4.677"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 19 Day 1 (n=71, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.94" spread="4.052"/>
                    <measurement group_id="O2" value="19.09" spread="5.224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 19 Day 28 (n=61, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.61" spread="4.469"/>
                    <measurement group_id="O2" value="18.20" spread="6.630"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 20 Day 1 (n=65, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.00" spread="4.138"/>
                    <measurement group_id="O2" value="18.67" spread="5.788"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 20 Day 28 (n=53, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.75" spread="4.206"/>
                    <measurement group_id="O2" value="18.67" spread="6.384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 1 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline Functional Assessment of Cancer Therapy-General (FACT-G) Emotional Well Being (EWB) subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.929</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.460</ci_lower_limit>
            <ci_upper_limit>1.398</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 1 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G EWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.922</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.469</ci_lower_limit>
            <ci_upper_limit>1.375</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 2 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G EWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.918</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.471</ci_lower_limit>
            <ci_upper_limit>1.365</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 2 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G EWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.911</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.469</ci_lower_limit>
            <ci_upper_limit>1.352</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 3 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G EWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.907</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.466</ci_lower_limit>
            <ci_upper_limit>1.348</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 3 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G EWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.899</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.453</ci_lower_limit>
            <ci_upper_limit>1.345</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 4 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G EWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.895</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.444</ci_lower_limit>
            <ci_upper_limit>1.347</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 4 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G EWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.888</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.421</ci_lower_limit>
            <ci_upper_limit>1.355</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 5 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G EWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.884</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.406</ci_lower_limit>
            <ci_upper_limit>1.362</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 5 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G EWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.877</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.375</ci_lower_limit>
            <ci_upper_limit>1.379</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 6 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G EWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0009</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.873</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.356</ci_lower_limit>
            <ci_upper_limit>1.390</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 6 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G EWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0020</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.866</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.318</ci_lower_limit>
            <ci_upper_limit>1.414</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 7 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G EWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0029</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.862</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.295</ci_lower_limit>
            <ci_upper_limit>1.428</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 7 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G EWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0055</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.854</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.251</ci_lower_limit>
            <ci_upper_limit>1.457</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 8 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G EWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0076</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.850</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.226</ci_lower_limit>
            <ci_upper_limit>1.475</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 8 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G EWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0129</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.843</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.179</ci_lower_limit>
            <ci_upper_limit>1.508</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 9 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G EWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0168</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.839</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.151</ci_lower_limit>
            <ci_upper_limit>1.527</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 9 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G EWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0257</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.832</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.101</ci_lower_limit>
            <ci_upper_limit>1.563</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 10 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G EWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0318</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.828</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.072</ci_lower_limit>
            <ci_upper_limit>1.583</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 10 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G EWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0447</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.821</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.019</ci_lower_limit>
            <ci_upper_limit>1.622</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 11 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G EWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0529</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.817</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.010</ci_lower_limit>
            <ci_upper_limit>1.643</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 11 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G EWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0696</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.809</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.065</ci_lower_limit>
            <ci_upper_limit>1.683</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 12 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G EWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0797</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.805</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.095</ci_lower_limit>
            <ci_upper_limit>1.706</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 12 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G EWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0994</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.798</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.151</ci_lower_limit>
            <ci_upper_limit>1.747</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 13 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G EWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1110</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.794</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.182</ci_lower_limit>
            <ci_upper_limit>1.770</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 13 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G EWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1328</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.787</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.239</ci_lower_limit>
            <ci_upper_limit>1.813</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 14 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G EWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1454</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.783</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.271</ci_lower_limit>
            <ci_upper_limit>1.836</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 14 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G EWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1686</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.776</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.329</ci_lower_limit>
            <ci_upper_limit>1.880</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 15 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G EWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1817</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.771</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.361</ci_lower_limit>
            <ci_upper_limit>1.904</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 15 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G EWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2055</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.764</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.419</ci_lower_limit>
            <ci_upper_limit>1.948</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 16 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G EWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2188</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.760</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.452</ci_lower_limit>
            <ci_upper_limit>1.972</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 16 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G EWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2427</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.753</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.510</ci_lower_limit>
            <ci_upper_limit>2.016</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 17 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G EWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2559</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.749</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.543</ci_lower_limit>
            <ci_upper_limit>2.041</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 17 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G EWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2794</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.742</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.602</ci_lower_limit>
            <ci_upper_limit>2.086</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 18 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G EWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2923</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.738</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.635</ci_lower_limit>
            <ci_upper_limit>2.111</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 18 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G EWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3152</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.730</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.695</ci_lower_limit>
            <ci_upper_limit>2.156</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 19 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G EWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3276</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.726</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.728</ci_lower_limit>
            <ci_upper_limit>2.181</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 19 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G EWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3497</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.719</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.788</ci_lower_limit>
            <ci_upper_limit>2.227</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 20 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G EWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3616</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.715</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.822</ci_lower_limit>
            <ci_upper_limit>2.252</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 20 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G EWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3827</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.708</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.882</ci_lower_limit>
            <ci_upper_limit>2.298</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Assessment of Cancer Therapy-General (FACT-G): Functional Well Being (FWB) Subscale</title>
        <description>Functional well-being (FWB) subscale of the Functional Assessment of Cancer Therapy-General (FACT-G). Each question was answered on a five-point Likert-type scale ranging from 0 to 4 (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). Score = the sum score of the item scores in the subscale; range: 0 to 28; higher score indicates greater functional well-being.</description>
        <time_frame>Day 1 &amp; 28 of each cycle: duration of treatment phase</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>SU011248</title>
            <description>50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered.</description>
          </group>
          <group group_id="O2">
            <title>IFN-α</title>
            <description>Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Assessment of Cancer Therapy-General (FACT-G): Functional Well Being (FWB) Subscale</title>
          <description>Functional well-being (FWB) subscale of the Functional Assessment of Cancer Therapy-General (FACT-G). Each question was answered on a five-point Likert-type scale ranging from 0 to 4 (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). Score = the sum score of the item scores in the subscale; range: 0 to 28; higher score indicates greater functional well-being.</description>
          <population>ITT</population>
          <units>scores on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="375"/>
                <count group_id="O2" value="375"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=371, 353)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.93" spread="6.107"/>
                    <measurement group_id="O2" value="18.51" spread="6.389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 28 (n=347, 318)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.92" spread="6.083"/>
                    <measurement group_id="O2" value="16.37" spread="6.694"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 1 (n=328, 249)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.78" spread="6.001"/>
                    <measurement group_id="O2" value="17.08" spread="6.279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 28 (n=315, 238)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.37" spread="6.210"/>
                    <measurement group_id="O2" value="17.18" spread="6.673"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 Day 1 (n=294, 200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.51" spread="6.073"/>
                    <measurement group_id="O2" value="17.92" spread="6.251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 Day 28 (n=287, 195)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.58" spread="5.994"/>
                    <measurement group_id="O2" value="17.56" spread="6.762"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 1 (n=272, 152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.93" spread="5.625"/>
                    <measurement group_id="O2" value="18.40" spread="6.382"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 28 (n=265, 142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.86" spread="5.694"/>
                    <measurement group_id="O2" value="18.37" spread="6.430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 Day 1 (n=249, 120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.27" spread="5.593"/>
                    <measurement group_id="O2" value="18.81" spread="5.697"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 Day 28 (n=241, 109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.02" spread="5.829"/>
                    <measurement group_id="O2" value="18.47" spread="6.065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 Day 1 (n=239, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.74" spread="5.608"/>
                    <measurement group_id="O2" value="19.02" spread="6.114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 Day 28 (n=222, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.21" spread="5.678"/>
                    <measurement group_id="O2" value="18.24" spread="6.273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 Day 1 (n=208, 79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.69" spread="5.645"/>
                    <measurement group_id="O2" value="18.45" spread="6.761"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 Day 28 (n=204, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.12" spread="5.798"/>
                    <measurement group_id="O2" value="18.76" spread="6.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8 Day 1 (n=192, 67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.29" spread="5.285"/>
                    <measurement group_id="O2" value="19.22" spread="5.828"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8 Day 28 (n=190, 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.33" spread="5.627"/>
                    <measurement group_id="O2" value="19.10" spread="6.098"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 9 Day 1 (n=170, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.87" spread="5.635"/>
                    <measurement group_id="O2" value="20.20" spread="5.455"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 9 Day 28 (n=167, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.27" spread="5.701"/>
                    <measurement group_id="O2" value="20.04" spread="5.929"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 Day 1 (n=161, 50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.95" spread="5.420"/>
                    <measurement group_id="O2" value="19.88" spread="5.903"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 Day 28 (n=154, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.22" spread="5.494"/>
                    <measurement group_id="O2" value="19.40" spread="6.126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 11 Day 1 (n=137, 35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.81" spread="5.368"/>
                    <measurement group_id="O2" value="18.89" spread="6.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 11 Day 28 (n=140, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.12" spread="5.749"/>
                    <measurement group_id="O2" value="18.81" spread="6.441"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 12 Day 1 (n=132, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.98" spread="5.618"/>
                    <measurement group_id="O2" value="18.80" spread="6.599"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 12 Day 28 (n=128, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.42" spread="5.755"/>
                    <measurement group_id="O2" value="19.13" spread="6.270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 Day 1 (n=114, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.02" spread="5.703"/>
                    <measurement group_id="O2" value="19.63" spread="6.918"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 Day 28 (n=114, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.65" spread="5.216"/>
                    <measurement group_id="O2" value="18.59" spread="6.795"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 14 Day 1 (n=114, 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.04" spread="5.556"/>
                    <measurement group_id="O2" value="19.62" spread="6.020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 14 Day 28 (n=107, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.07" spread="6.025"/>
                    <measurement group_id="O2" value="19.72" spread="6.662"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 15 Day 1 (n=101, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.13" spread="5.654"/>
                    <measurement group_id="O2" value="19.86" spread="6.327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 15 Day 28 (n=96, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.24" spread="5.589"/>
                    <measurement group_id="O2" value="19.83" spread="5.736"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 Day 1 (n=96, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.80" spread="5.469"/>
                    <measurement group_id="O2" value="18.89" spread="6.154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 Day 28 (n=91, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.53" spread="5.313"/>
                    <measurement group_id="O2" value="18.61" spread="6.464"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 17 Day 1 (n=85, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.20" spread="5.606"/>
                    <measurement group_id="O2" value="19.35" spread="6.103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 17 Day 28 (n=81, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.67" spread="5.662"/>
                    <measurement group_id="O2" value="18.71" spread="6.557"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 18 Day 1 (n=80, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.76" spread="5.862"/>
                    <measurement group_id="O2" value="19.08" spread="7.317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 18 Day 28 (n=71, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.47" spread="5.526"/>
                    <measurement group_id="O2" value="19.00" spread="7.155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 19 Day 1 (n=71, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.18" spread="5.563"/>
                    <measurement group_id="O2" value="19.64" spread="7.500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 19 Day 28 (n=61, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.59" spread="6.326"/>
                    <measurement group_id="O2" value="19.10" spread="8.048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 20 Day 1 (n=65, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.50" spread="5.425"/>
                    <measurement group_id="O2" value="20.00" spread="7.826"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 20 Day 28 (n=53, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.15" spread="5.819"/>
                    <measurement group_id="O2" value="20.22" spread="7.694"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 1 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline Functional Assessment of Cancer Therapy-General (FACT-G) Functional Well Being (FWB) subscale baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.897</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.261</ci_lower_limit>
            <ci_upper_limit>2.533</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 1 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G FWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.924</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.309</ci_lower_limit>
            <ci_upper_limit>2.539</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 2 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G FWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.939</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.331</ci_lower_limit>
            <ci_upper_limit>2.546</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 2 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G FWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.965</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.363</ci_lower_limit>
            <ci_upper_limit>2.568</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 3 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G FWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.980</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.376</ci_lower_limit>
            <ci_upper_limit>2.584</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 3 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G FWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.007</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.392</ci_lower_limit>
            <ci_upper_limit>2.622</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 4 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G FWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.022</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.396</ci_lower_limit>
            <ci_upper_limit>2.647</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 4 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G FWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.048</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.397</ci_lower_limit>
            <ci_upper_limit>2.700</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 5 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G FWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.063</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.394</ci_lower_limit>
            <ci_upper_limit>2.732</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 5 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G FWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.090</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.383</ci_lower_limit>
            <ci_upper_limit>2.797</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 6 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G FWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.105</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.374</ci_lower_limit>
            <ci_upper_limit>2.836</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 6 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G FWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.132</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.353</ci_lower_limit>
            <ci_upper_limit>2.910</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 7 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G FWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.146</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.339</ci_lower_limit>
            <ci_upper_limit>2.954</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 7 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G FWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.173</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.311</ci_lower_limit>
            <ci_upper_limit>3.036</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 8 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G FWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.188</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.294</ci_lower_limit>
            <ci_upper_limit>3.082</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 8 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G FWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.215</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.260</ci_lower_limit>
            <ci_upper_limit>3.169</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 9 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G FWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.230</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.241</ci_lower_limit>
            <ci_upper_limit>3.219</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 9 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G FWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.256</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.203</ci_lower_limit>
            <ci_upper_limit>3.309</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 10 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G FWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.271</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.182</ci_lower_limit>
            <ci_upper_limit>3.361</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 10 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G FWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.298</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.142</ci_lower_limit>
            <ci_upper_limit>3.454</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 11 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G FWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.313</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.119</ci_lower_limit>
            <ci_upper_limit>3.507</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 11 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G FWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.340</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.076</ci_lower_limit>
            <ci_upper_limit>3.603</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 12 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G FWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.354</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.052</ci_lower_limit>
            <ci_upper_limit>3.657</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 12 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G FWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0007</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.381</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.008</ci_lower_limit>
            <ci_upper_limit>3.754</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 13 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G FWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0009</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.396</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.983</ci_lower_limit>
            <ci_upper_limit>3.809</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 13 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G FWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0014</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.423</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.938</ci_lower_limit>
            <ci_upper_limit>3.908</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 14 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G FWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0017</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.438</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.912</ci_lower_limit>
            <ci_upper_limit>3.963</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 14 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G FWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0025</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.464</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.866</ci_lower_limit>
            <ci_upper_limit>4.063</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 15 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G FWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0030</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.479</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.840</ci_lower_limit>
            <ci_upper_limit>4.119</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 15 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G FWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0042</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.506</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.792</ci_lower_limit>
            <ci_upper_limit>4.219</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 16 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G FWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0049</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.521</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.766</ci_lower_limit>
            <ci_upper_limit>4.275</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 16 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G FWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0064</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.547</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.718</ci_lower_limit>
            <ci_upper_limit>4.377</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 17 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G FWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0073</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.562</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.691</ci_lower_limit>
            <ci_upper_limit>4.433</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 17 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G FWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0091</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.589</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.643</ci_lower_limit>
            <ci_upper_limit>4.535</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 18 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G FWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0103</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.604</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.616</ci_lower_limit>
            <ci_upper_limit>4.592</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 18 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G FWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0125</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.631</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.567</ci_lower_limit>
            <ci_upper_limit>4.695</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 19 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G FWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0138</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.645</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.539</ci_lower_limit>
            <ci_upper_limit>4.752</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 19 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G FWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0164</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.672</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.490</ci_lower_limit>
            <ci_upper_limit>4.855</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 20 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G FWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0179</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.687</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.462</ci_lower_limit>
            <ci_upper_limit>4.912</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 20 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline FACT—G FWB subscale baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0208</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.714</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.413</ci_lower_limit>
            <ci_upper_limit>5.015</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EuroQoL Five Dimension (EQ-5D) Health State Index</title>
        <description>EQ-5D Health State Index: a brief, self-administered generic health status instrument. Respondents were asked to describe their current health state on each of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety or depression) on a three-level scale (1=no problem, 2=some problem, and 3=extreme problem). A maximum score of 1 can be derived from these 5 dimensions by score conversion; range: –0.39 (worst health state)to 1.00 (best health state). This descriptive system classifies respondents into one of 243 possible distinct health states (EQ-5D descriptive system).</description>
        <time_frame>Day 1 &amp; 28 of each cycle: duration of treatment phase</time_frame>
        <population>ITT; N=number of subjects with evaluable data; n=number of subjects with evaluable data at observation.</population>
        <group_list>
          <group group_id="O1">
            <title>SU011248</title>
            <description>50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered.</description>
          </group>
          <group group_id="O2">
            <title>IFN-α</title>
            <description>Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>EuroQoL Five Dimension (EQ-5D) Health State Index</title>
          <description>EQ-5D Health State Index: a brief, self-administered generic health status instrument. Respondents were asked to describe their current health state on each of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety or depression) on a three-level scale (1=no problem, 2=some problem, and 3=extreme problem). A maximum score of 1 can be derived from these 5 dimensions by score conversion; range: –0.39 (worst health state)to 1.00 (best health state). This descriptive system classifies respondents into one of 243 possible distinct health states (EQ-5D descriptive system).</description>
          <population>ITT; N=number of subjects with evaluable data; n=number of subjects with evaluable data at observation.</population>
          <units>scores on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="375"/>
                <count group_id="O2" value="375"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=363, 352)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" spread="0.225"/>
                    <measurement group_id="O2" value="0.76" spread="0.234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 28 (346, 315)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72" spread="0.262"/>
                    <measurement group_id="O2" value="0.70" spread="0.274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 1 (326, 244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.78" spread="0.230"/>
                    <measurement group_id="O2" value="0.75" spread="0.231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 28 (311, 233)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" spread="0.246"/>
                    <measurement group_id="O2" value="0.74" spread="0.230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 Day 1 (287, 200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.78" spread="0.220"/>
                    <measurement group_id="O2" value="0.76" spread="0.222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 Day 28 (283, 195)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" spread="0.231"/>
                    <measurement group_id="O2" value="0.75" spread="0.218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 1 (269, 150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80" spread="0.199"/>
                    <measurement group_id="O2" value="0.80" spread="0.190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 28 (261, 142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" spread="0.218"/>
                    <measurement group_id="O2" value="0.79" spread="0.216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 Day 1 (247, 120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80" spread="0.209"/>
                    <measurement group_id="O2" value="0.79" spread="0.194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 Day 28 (240, 106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" spread="0.223"/>
                    <measurement group_id="O2" value="0.78" spread="0.201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 Day 1 (240, 98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80" spread="0.249"/>
                    <measurement group_id="O2" value="0.80" spread="0.178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 Day 28 (224, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" spread="0.206"/>
                    <measurement group_id="O2" value="0.80" spread="0.187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 Day 1 (205, 79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" spread="0.192"/>
                    <measurement group_id="O2" value="0.80" spread="0.185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 Day 28 (204, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" spread="0.221"/>
                    <measurement group_id="O2" value="0.81" spread="0.156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8 Day 1 (192, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.82" spread="0.180"/>
                    <measurement group_id="O2" value="0.82" spread="0.158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8 Day 28 (190, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" spread="0.222"/>
                    <measurement group_id="O2" value="0.81" spread="0.163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 9 Day 1 (170, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80" spread="0.196"/>
                    <measurement group_id="O2" value="0.84" spread="0.162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 9 Day 28 (168, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.78" spread="0.194"/>
                    <measurement group_id="O2" value="0.84" spread="0.147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 Day 1 (161, 50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" spread="0.209"/>
                    <measurement group_id="O2" value="0.85" spread="0.161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 Day 28 (153, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.78" spread="0.200"/>
                    <measurement group_id="O2" value="0.82" spread="0.185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 11 Day 1 (138, 34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80" spread="0.192"/>
                    <measurement group_id="O2" value="0.85" spread="0.159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 11 Day 28 (138, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" spread="0.189"/>
                    <measurement group_id="O2" value="0.84" spread="0.185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 12 Day 1 (132, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" spread="0.187"/>
                    <measurement group_id="O2" value="0.82" spread="0.283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 12 Day 28 (127, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" spread="0.182"/>
                    <measurement group_id="O2" value="0.85" spread="0.165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 Day 1 (114, 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" spread="0.176"/>
                    <measurement group_id="O2" value="0.83" spread="0.231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 Day 28 (115, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" spread="0.186"/>
                    <measurement group_id="O2" value="0.82" spread="0.260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 14 Day 1 (114, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" spread="0.181"/>
                    <measurement group_id="O2" value="0.86" spread="0.148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 14 Day 28 (107, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" spread="0.224"/>
                    <measurement group_id="O2" value="0.87" spread="0.160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 15 Day 1 (100, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80" spread="0.190"/>
                    <measurement group_id="O2" value="0.88" spread="0.146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 15 Day 28 (95, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" spread="0.209"/>
                    <measurement group_id="O2" value="0.88" spread="0.141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 Day 1 (96, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79" spread="0.194"/>
                    <measurement group_id="O2" value="0.84" spread="0.163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 Day 28 (93, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" spread="0.181"/>
                    <measurement group_id="O2" value="0.83" spread="0.164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 17 Day 1 (84, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79" spread="0.194"/>
                    <measurement group_id="O2" value="0.88" spread="0.169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 17 Day 28 (82, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" spread="0.168"/>
                    <measurement group_id="O2" value="0.83" spread="0.174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 18 Day 1 (80, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" spread="0.187"/>
                    <measurement group_id="O2" value="0.86" spread="0.274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 18 Day 28 (71, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" spread="0.166"/>
                    <measurement group_id="O2" value="0.84" spread="0.279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 19 Day 1 (69, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" spread="0.183"/>
                    <measurement group_id="O2" value="0.88" spread="0.184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 19 Day 28 (62, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.78" spread="0.165"/>
                    <measurement group_id="O2" value="0.72" spread="0.436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 20 Day 1 (63, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" spread="0.162"/>
                    <measurement group_id="O2" value="0.85" spread="0.182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 20 Day 28 (54, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" spread="0.181"/>
                    <measurement group_id="O2" value="0.86" spread="0.215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 1 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EuroQoL Five Dimension (EQ-5D): Health state index baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.049</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.022</ci_lower_limit>
            <ci_upper_limit>0.076</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 1 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—5D Health state index baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.048</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.022</ci_lower_limit>
            <ci_upper_limit>0.075</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 2 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—5D Health state index baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.048</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.022</ci_lower_limit>
            <ci_upper_limit>0.074</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 2 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—5D Health state index baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.047</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.021</ci_lower_limit>
            <ci_upper_limit>0.072</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 3 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—5D Health state index baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.046</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.021</ci_lower_limit>
            <ci_upper_limit>0.072</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 3 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—5D Health state index baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.045</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.020</ci_lower_limit>
            <ci_upper_limit>0.071</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 4 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—5D Health state index baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0007</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.045</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.019</ci_lower_limit>
            <ci_upper_limit>0.070</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 4 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—5D Health state index baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0011</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.044</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.017</ci_lower_limit>
            <ci_upper_limit>0.070</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 5 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—5D Health state index baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0016</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.043</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.016</ci_lower_limit>
            <ci_upper_limit>0.070</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 5 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—5D Health state index baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0029</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.042</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.014</ci_lower_limit>
            <ci_upper_limit>0.070</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 6 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—5D Health state index baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0041</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.042</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.013</ci_lower_limit>
            <ci_upper_limit>0.070</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 6 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—5D Health state index baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0076</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.041</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.011</ci_lower_limit>
            <ci_upper_limit>0.071</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 7 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—5D Health state index baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0105</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.040</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.009</ci_lower_limit>
            <ci_upper_limit>0.071</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 7 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—5D Health state index baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0179</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.039</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.007</ci_lower_limit>
            <ci_upper_limit>0.072</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 8 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—5D Health state index baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0236</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.039</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.005</ci_lower_limit>
            <ci_upper_limit>0.072</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 8 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—5D Health state index baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0370</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.038</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.002</ci_lower_limit>
            <ci_upper_limit>0.073</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 9 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—5D Health state index baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0464</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.037</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.001</ci_lower_limit>
            <ci_upper_limit>0.074</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 9 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—5D Health state index baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0667</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.036</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.002</ci_lower_limit>
            <ci_upper_limit>0.075</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 10 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—5D Health state index baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0800</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.036</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.004</ci_lower_limit>
            <ci_upper_limit>0.076</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 10 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—5D Health state index baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1070</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.035</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.007</ci_lower_limit>
            <ci_upper_limit>0.077</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 11 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—5D Health state index baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1237</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.034</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.009</ci_lower_limit>
            <ci_upper_limit>0.078</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 11 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—5D Health state index baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1561</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.033</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.013</ci_lower_limit>
            <ci_upper_limit>0.079</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 12 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—5D Health state index baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1752</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.033</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.015</ci_lower_limit>
            <ci_upper_limit>0.080</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 12 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—5D Health state index baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2112</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.032</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.018</ci_lower_limit>
            <ci_upper_limit>0.081</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 13 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—5D Health state index baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2319</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.031</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.020</ci_lower_limit>
            <ci_upper_limit>0.082</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 13 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—5D Health state index baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2698</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.030</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.023</ci_lower_limit>
            <ci_upper_limit>0.084</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 14 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—5D Health state index baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2910</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.030</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.025</ci_lower_limit>
            <ci_upper_limit>0.085</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 14 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—5D Health state index baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3293</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.029</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.029</ci_lower_limit>
            <ci_upper_limit>0.086</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 15 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—5D Health state index baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3504</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.028</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.031</ci_lower_limit>
            <ci_upper_limit>0.087</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 15 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—5D Health state index baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3881</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.027</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.034</ci_lower_limit>
            <ci_upper_limit>0.089</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 16 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—5D Health state index baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4086</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.027</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.036</ci_lower_limit>
            <ci_upper_limit>0.090</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 16 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—5D Health state index baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4449</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.026</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.040</ci_lower_limit>
            <ci_upper_limit>0.091</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 17 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—5D Health state index baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4646</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.025</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.042</ci_lower_limit>
            <ci_upper_limit>0.092</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 17 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—5D Health state index baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4990</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.024</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.046</ci_lower_limit>
            <ci_upper_limit>0.094</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 18 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—5D Health state index baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5176</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.024</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.048</ci_lower_limit>
            <ci_upper_limit>0.095</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 18 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—5D Health state index baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5501</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.023</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.051</ci_lower_limit>
            <ci_upper_limit>0.097</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 19 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—5D Health state index baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5675</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.022</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.054</ci_lower_limit>
            <ci_upper_limit>0.098</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 19 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—5D Health state index baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5979</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.021</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.057</ci_lower_limit>
            <ci_upper_limit>0.099</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 20 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—5D Health state index baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6141</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.021</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.059</ci_lower_limit>
            <ci_upper_limit>0.100</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 20 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—5D Health state index baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6424</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.020</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.063</ci_lower_limit>
            <ci_upper_limit>0.102</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Euro-QoL Visual Analog Scale (EQ-VAS)</title>
        <description>EQ-VAS: overall self-rating rating of the patient’s current health state using a 20 cm Visual Analog Scale (EQ-VAS), also called the health state thermometer) is a metric measurement (in 2 mm interval) from the visual analog scale which ranges between 0 (worse imaginable health state) and 100 (best imaginable health state).</description>
        <time_frame>Day 1 &amp; 28 of each cycle: duration of treatment phase</time_frame>
        <population>ITT; N=number of subjects with evaluable data; n=number of subjects with evaluable data at observation.</population>
        <group_list>
          <group group_id="O1">
            <title>SU011248</title>
            <description>50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered.</description>
          </group>
          <group group_id="O2">
            <title>IFN-α</title>
            <description>Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Euro-QoL Visual Analog Scale (EQ-VAS)</title>
          <description>EQ-VAS: overall self-rating rating of the patient’s current health state using a 20 cm Visual Analog Scale (EQ-VAS), also called the health state thermometer) is a metric measurement (in 2 mm interval) from the visual analog scale which ranges between 0 (worse imaginable health state) and 100 (best imaginable health state).</description>
          <population>ITT; N=number of subjects with evaluable data; n=number of subjects with evaluable data at observation.</population>
          <units>scores on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="375"/>
                <count group_id="O2" value="375"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=365, 352)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.80" spread="18.498"/>
                    <measurement group_id="O2" value="71.43" spread="19.507"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 28 (n=347, 315)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.35" spread="18.992"/>
                    <measurement group_id="O2" value="67.66" spread="20.058"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 1 (n=323, 247)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.05" spread="17.964"/>
                    <measurement group_id="O2" value="70.45" spread="17.653"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 28 (n=314, 237)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.06" spread="18.297"/>
                    <measurement group_id="O2" value="70.70" spread="18.271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 Day 1 (n=293, 198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.23" spread="17.171"/>
                    <measurement group_id="O2" value="72.68" spread="17.162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 Day 28 (n=287, 193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.33" spread="18.472"/>
                    <measurement group_id="O2" value="71.45" spread="18.315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 1 (n=270, 152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.46" spread="16.024"/>
                    <measurement group_id="O2" value="72.74" spread="17.678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 28 (n=264, 139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.15" spread="16.406"/>
                    <measurement group_id="O2" value="72.20" spread="18.098"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 Day 1 (n=248, 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.83" spread="13.554"/>
                    <measurement group_id="O2" value="73.44" spread="16.204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 Day 28 (n=240, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.13" spread="16.771"/>
                    <measurement group_id="O2" value="72.57" spread="16.007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 Day 1 (n=237, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.83" spread="15.359"/>
                    <measurement group_id="O2" value="73.68" spread="16.537"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 Day 28 (n=223, 98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.81" spread="15.204"/>
                    <measurement group_id="O2" value="72.26" spread="18.452"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 Day 1 (n=209, 77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.39" spread="14.601"/>
                    <measurement group_id="O2" value="73.80" spread="18.868"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 Day 28 (n=201, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.09" spread="16.693"/>
                    <measurement group_id="O2" value="73.46" spread="17.380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8 Day 1 (n=192, 67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.34" spread="13.020"/>
                    <measurement group_id="O2" value="74.27" spread="18.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8 Day 28 (n=191, 60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.53" spread="14.374"/>
                    <measurement group_id="O2" value="74.33" spread="18.407"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 9 Day 1 (n=172, 50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.08" spread="13.812"/>
                    <measurement group_id="O2" value="77.66" spread="15.987"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 9 Day 28 (n=168, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.24" spread="15.740"/>
                    <measurement group_id="O2" value="76.57" spread="17.924"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 Day 1 (n=160, 50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.18" spread="14.912"/>
                    <measurement group_id="O2" value="76.64" spread="17.886"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 Day 28 (n=154, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.44" spread="16.106"/>
                    <measurement group_id="O2" value="76.69" spread="19.123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 11 Day 1 (n=138, 34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.72" spread="15.685"/>
                    <measurement group_id="O2" value="75.06" spread="20.179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 11 Day 28 (n=141, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.81" spread="15.128"/>
                    <measurement group_id="O2" value="72.21" spread="23.202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 12 Day 1 (n=130, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.84" spread="14.150"/>
                    <measurement group_id="O2" value="75.19" spread="22.020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 12 Day 28 (n=128, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.71" spread="14.986"/>
                    <measurement group_id="O2" value="73.84" spread="20.775"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 Day 1 (n=114, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.59" spread="14.875"/>
                    <measurement group_id="O2" value="77.52" spread="17.738"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 Day 28 (n=115, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.22" spread="14.715"/>
                    <measurement group_id="O2" value="73.56" spread="23.523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 14 Day 1 (n=114, 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.39" spread="14.477"/>
                    <measurement group_id="O2" value="76.69" spread="16.601"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 14 Day 28 (n=107, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.53" spread="15.933"/>
                    <measurement group_id="O2" value="76.44" spread="18.890"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 15 Day 1 (n=101, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.50" spread="14.361"/>
                    <measurement group_id="O2" value="76.62" spread="19.075"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 15 Day 28 (n=96, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.51" spread="15.141"/>
                    <measurement group_id="O2" value="76.50" spread="18.841"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 Day 1 (n=96, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.85" spread="15.632"/>
                    <measurement group_id="O2" value="74.84" spread="21.680"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 Day 28 (n=92, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.51" spread="17.687"/>
                    <measurement group_id="O2" value="73.11" spread="21.202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 17 Day 1 (n=84, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.74" spread="15.706"/>
                    <measurement group_id="O2" value="76.94" spread="21.256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 17 Day 28 (n=82, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.10" spread="16.612"/>
                    <measurement group_id="O2" value="72.86" spread="22.593"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 18 Day 1 (n=78, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.40" spread="14.658"/>
                    <measurement group_id="O2" value="74.42" spread="25.065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 18 Day 28 (n=70, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.76" spread="16.142"/>
                    <measurement group_id="O2" value="73.82" spread="24.140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 19 Day 1 (n=70, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.47" spread="15.330"/>
                    <measurement group_id="O2" value="79.27" spread="20.283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 19 Day 28 (n=62, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.05" spread="18.676"/>
                    <measurement group_id="O2" value="68.55" spread="29.717"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 20 Day 1 (n=65, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.10" spread="15.404"/>
                    <measurement group_id="O2" value="76.00" spread="21.494"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 20 Day 28 (n=54, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.85" spread="16.863"/>
                    <measurement group_id="O2" value="75.44" spread="25.060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 1 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline Euro-QoL Visual Analog Scale (EQ—VAS) baseline score (intercept and time since randomization are included as random effects).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.026</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.088</ci_lower_limit>
            <ci_upper_limit>5.965</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 1 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—VAS baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.165</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.269</ci_lower_limit>
            <ci_upper_limit>6.061</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 2 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—VAS baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.243</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.358</ci_lower_limit>
            <ci_upper_limit>6.128</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 2 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—VAS baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.382</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.494</ci_lower_limit>
            <ci_upper_limit>6.269</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 3 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—VAS baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.459</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.558</ci_lower_limit>
            <ci_upper_limit>6.361</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 3 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—VAS baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.598</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.650</ci_lower_limit>
            <ci_upper_limit>6.547</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 4 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—VAS baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.676</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.689</ci_lower_limit>
            <ci_upper_limit>6.662</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 4 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—VAS baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.815</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.741</ci_lower_limit>
            <ci_upper_limit>6.889</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 5 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—VAS baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.892</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.760</ci_lower_limit>
            <ci_upper_limit>7.024</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 5 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—VAS baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.031</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.780</ci_lower_limit>
            <ci_upper_limit>7.283</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 6 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—VAS baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.109</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.783</ci_lower_limit>
            <ci_upper_limit>7.435</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 6 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—VAS baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.248</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.776</ci_lower_limit>
            <ci_upper_limit>7.720</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 7 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—VAS baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.325</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.767</ci_lower_limit>
            <ci_upper_limit>7.884</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 7 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—VAS baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.464</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.741</ci_lower_limit>
            <ci_upper_limit>8.188</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 8 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—VAS baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.542</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.723</ci_lower_limit>
            <ci_upper_limit>8.361</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 8 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—VAS baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.681</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.683</ci_lower_limit>
            <ci_upper_limit>8.679</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 9 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—VAS baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.758</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.657</ci_lower_limit>
            <ci_upper_limit>8.859</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 9 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—VAS baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.898</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.607</ci_lower_limit>
            <ci_upper_limit>9.188</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 10 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—VAS baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.975</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.576</ci_lower_limit>
            <ci_upper_limit>9.374</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 10 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—VAS baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0009</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.114</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.517</ci_lower_limit>
            <ci_upper_limit>9.711</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 11 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—VAS baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0011</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.191</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.482</ci_lower_limit>
            <ci_upper_limit>9.900</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 11 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—VAS baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0015</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.331</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.417</ci_lower_limit>
            <ci_upper_limit>10.244</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 12 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—VAS baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0018</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.408</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.379</ci_lower_limit>
            <ci_upper_limit>10.436</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 12 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—VAS baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0025</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.547</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.309</ci_lower_limit>
            <ci_upper_limit>10.785</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 13 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—VAS baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0029</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.624</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.269</ci_lower_limit>
            <ci_upper_limit>10.980</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 13 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—VAS baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0037</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.764</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.195</ci_lower_limit>
            <ci_upper_limit>11.332</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 14 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—VAS baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0042</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.841</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.153</ci_lower_limit>
            <ci_upper_limit>11.529</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 14 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—VAS baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0053</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.980</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.076</ci_lower_limit>
            <ci_upper_limit>11.884</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 15 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—VAS baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0059</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.057</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.032</ci_lower_limit>
            <ci_upper_limit>12.083</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 15 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—VAS baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0072</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.197</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.953</ci_lower_limit>
            <ci_upper_limit>12.441</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 16 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—VAS baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0079</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.274</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.908</ci_lower_limit>
            <ci_upper_limit>12.640</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 16 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—VAS baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0093</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.413</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.826</ci_lower_limit>
            <ci_upper_limit>13.000</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 17 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—VAS baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0101</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.491</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.780</ci_lower_limit>
            <ci_upper_limit>13.201</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 17 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—VAS baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0117</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.630</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.697</ci_lower_limit>
            <ci_upper_limit>13.562</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 18 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—VAS baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0126</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.707</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.650</ci_lower_limit>
            <ci_upper_limit>13.764</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 18 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—VAS baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0144</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.846</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.565</ci_lower_limit>
            <ci_upper_limit>14.127</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 19 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—VAS baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0153</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.924</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.518</ci_lower_limit>
            <ci_upper_limit>14.329</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 19 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—VAS baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0172</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>8.063</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.432</ci_lower_limit>
            <ci_upper_limit>14.693</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 20 Day 1: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—VAS baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0182</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>8.140</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.384</ci_lower_limit>
            <ci_upper_limit>14.896</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cycle 20 Day 28: Differences in effect estimates between treatment arms. Repeated measures mixed—effects model with an intercept term, treatment, time since randomization, treatment—by—time interaction, and baseline EQ—VAS baseline score (intercept and time since randomization are included as random effects)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0201</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>8.279</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.297</ci_lower_limit>
            <ci_upper_limit>15.261</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentrations of Soluble Proteins: Plasma VEGF-A, Plasma VEGF-C, Plasma sVEGFR-3, PLASMA IL-8, and PLASMA bFGF That May be Associated With Tumor Proliferation or Angiogenesis</title>
        <description>Plasma concentrations of soluble proteins that may be associated with tumor proliferation or angiogenesis collected from a subset of patients were analyzed by enzyme-linked immunosorbent assay (ELISA) analysis. Soluble protein values: Baseline concentration (pM) and ratio to Baseline at each timepoint; ratio = plasma concentration of soluble protein (picograms per milliliter [pg/ml]) at timepoint / concentration of soluble protein (pg/ml) at baseline. Samples below the limit of quantitation and samples with insufficient volume available were excluded.</description>
        <time_frame>Day 1 &amp; Day 28, Cycle 1 to Cycle 4</time_frame>
        <population>Pharmacodynamic analyses performed at selected sites on AT population who had at least one pharmacokinetic sample; n= SU011248, INF-α; Abbreviations: C: Cycle, D: Day, VEGF: vascular endothelial growth factor, sVEGFR-3: soluble vascular endothelial growth factor Receptor-3, IL-8: interleukin-8, bFGF: basic fibroblast growth factor.</population>
        <group_list>
          <group group_id="O1">
            <title>SU011248</title>
            <description>50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered.</description>
          </group>
          <group group_id="O2">
            <title>IFN-α</title>
            <description>Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentrations of Soluble Proteins: Plasma VEGF-A, Plasma VEGF-C, Plasma sVEGFR-3, PLASMA IL-8, and PLASMA bFGF That May be Associated With Tumor Proliferation or Angiogenesis</title>
          <description>Plasma concentrations of soluble proteins that may be associated with tumor proliferation or angiogenesis collected from a subset of patients were analyzed by enzyme-linked immunosorbent assay (ELISA) analysis. Soluble protein values: Baseline concentration (pM) and ratio to Baseline at each timepoint; ratio = plasma concentration of soluble protein (picograms per milliliter [pg/ml]) at timepoint / concentration of soluble protein (pg/ml) at baseline. Samples below the limit of quantitation and samples with insufficient volume available were excluded.</description>
          <population>Pharmacodynamic analyses performed at selected sites on AT population who had at least one pharmacokinetic sample; n= SU011248, INF-α; Abbreviations: C: Cycle, D: Day, VEGF: vascular endothelial growth factor, sVEGFR-3: soluble vascular endothelial growth factor Receptor-3, IL-8: interleukin-8, bFGF: basic fibroblast growth factor.</population>
          <units>pg/ml and ratio to Baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Plasma VEGF-A: Baseline (n=33, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.9" spread="184.3"/>
                    <measurement group_id="O2" value="109.0" spread="242.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma VEGF-A: C1D28: C1D1 (n=31, 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.280" spread="2.619"/>
                    <measurement group_id="O2" value="1.134" spread="0.683"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma VEGF-A: C2D1: C1D1 (n=32, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.161" spread="0.624"/>
                    <measurement group_id="O2" value="1.171" spread="0.527"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma VEGF-A: C2D28: C1D1 (n=31, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.851" spread="4.345"/>
                    <measurement group_id="O2" value="1.153" spread="0.517"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma VEGF-A: C3D1: C1D1 (n=27, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.630" spread="1.685"/>
                    <measurement group_id="O2" value="1.253" spread="0.483"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma VEGF-A: C3D28: C1D1 (n=28, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.236" spread="3.333"/>
                    <measurement group_id="O2" value="1.149" spread="0.570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma VEGF-A: C4D1: C1D1 (n=27, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.486" spread="1.125"/>
                    <measurement group_id="O2" value="1.209" spread="0.654"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma VEGF-A: C4D28: C1D1 (n=25, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.924" spread="3.679"/>
                    <measurement group_id="O2" value="1.008" spread="0.372"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma VEGF-C: Baseline (n=35, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="556.4" spread="311.7"/>
                    <measurement group_id="O2" value="651.2" spread="552.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma VEGF-C: C1D28: C1D1 (n=31, 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.945" spread="0.428"/>
                    <measurement group_id="O2" value="1.165" spread="0.606"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma VEGF-C: C2D1:C1D1 (n=30, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.045" spread="0.623"/>
                    <measurement group_id="O2" value="1.177" spread="0.464"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma VEGF-C: C2D28:C1D1 (n=31, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.871" spread="0.511"/>
                    <measurement group_id="O2" value="1.081" spread="0.410"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma VEGF-C: C3D1:C1D1 (n=28, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.159" spread="0.659"/>
                    <measurement group_id="O2" value="1.174" spread="0.588"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma VEGF-C: C3D28:C1D1 (n=28, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.043" spread="0.926"/>
                    <measurement group_id="O2" value="1.054" spread="0.586"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma VEGF-C: C4D1:C1D1 (n=28, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.243" spread="1.304"/>
                    <measurement group_id="O2" value="1.382" spread="0.799"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma VEGF-C: C4:D28:C1D1 (n=26, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.207" spread="1.269"/>
                    <measurement group_id="O2" value="1.139" spread="0.403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLASMA sVEGFR-3: Baseline (n=29, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44049.3" spread="20168.2"/>
                    <measurement group_id="O2" value="40317.7" spread="12938.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLASMA sVEGFR-3: C1D28:C1D1 (n=27, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.473" spread="0.185"/>
                    <measurement group_id="O2" value="1.068" spread="0.292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLASMA sVEGFR-3: C2D1:C1D1 (n=28, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.787" spread="0.172"/>
                    <measurement group_id="O2" value="1.075" spread="0.331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLASMA sVEGFR-3: C2D28:C1D1 (n=28, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.407" spread="0.173"/>
                    <measurement group_id="O2" value="1.150" spread="0.355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLASMA sVEGFR-3: C3D1:C1D1 (n=25, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.800" spread="0.309"/>
                    <measurement group_id="O2" value="1.015" spread="0.210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLASMA sVEGFR-3: C3D28:C1D1 (n=25, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.427" spread="0.194"/>
                    <measurement group_id="O2" value="1.042" spread="0.349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLASMA sVEGFR-3: C4D1:C1D1 (n=24, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.846" spread="0.380"/>
                    <measurement group_id="O2" value="1.183" spread="0.333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLASMA sVEGFR-3: C4:D28:C1D1 (n=23, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.486" spread="0.265"/>
                    <measurement group_id="O2" value="1.044" spread="0.141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLASMA IL-8: Baseline (n=31, 29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" spread="9.7"/>
                    <measurement group_id="O2" value="18.6" spread="32.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLASMA IL-8: C1D28:C1D1 (n=29, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.815" spread="1.340"/>
                    <measurement group_id="O2" value="2.297" spread="2.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLASMA IL-8: C2D1:C1D1 (n=29, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.716" spread="0.630"/>
                    <measurement group_id="O2" value="1.579" spread="0.688"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLASMA IL-8: C2D28:C1D1 (n=29, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.423" spread="1.514"/>
                    <measurement group_id="O2" value="1.858" spread="0.849"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLASMA IL-8: C3D1:C1D1 (n=26, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.788" spread="2.781"/>
                    <measurement group_id="O2" value="1.531" spread="0.693"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLASMA IL-8: C3D28:C1D1 (n=26, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.574" spread="1.726"/>
                    <measurement group_id="O2" value="1.999" spread="0.964"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLASMA IL-8: C4D1:C1D1 (n=26, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.934" spread="1.372"/>
                    <measurement group_id="O2" value="1.662" spread="0.736"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLASMA IL-8: C4:D28:C1D1 (n=25, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.549" spread="1.489"/>
                    <measurement group_id="O2" value="2.492" spread="2.023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLASMA bFGF: Baseline (n=21, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1" spread="13.1"/>
                    <measurement group_id="O2" value="13.6" spread="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLASMA bFGF: C1D28:C1D1 (n=15, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.762" spread="5.087"/>
                    <measurement group_id="O2" value="0.429" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLASMA bFGF: C2D1:C1D1 (n=13, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.370" spread="1.800"/>
                    <measurement group_id="O2" value="0.157" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentrations of Soluble Proteins: Plasma Basic Fibroblast Growth Factor (bFGF) That May be Associated With Tumor Proliferation or Angiogenesis</title>
        <description>Plasma concentrations of soluble proteins that may be associated with tumor proliferation or angiogenesis collected from a subset of patients were analyzed by enzyme-linked immunosorbent assay (ELISA) analysis. Soluble protein values: Baseline concentration (pM) and ratio to Baseline at each timepoint; ratio = plasma concentration of soluble protein (picograms per milliliter [pg/ml]) at timepoint / concentration of soluble protein (pg/ml) at baseline. Samples below the limit of quantitation and samples with insufficient volume available were excluded.</description>
        <time_frame>Day 1 &amp; Day 28, Cycle 1 to Cycle 4</time_frame>
        <population>Pharmacodynamic analyses performed at selected sites on AT population who had at least one PK (pharmacokinetic) sample; n = subjects with evaluable data at observation, SU011248 and INF-α treatment groups, respectively. Abbreviations: C = Cycle, D = Day, bFGF: basic fibroblast growth factor.</population>
        <group_list>
          <group group_id="O1">
            <title>SU011248</title>
            <description>50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered.</description>
          </group>
          <group group_id="O2">
            <title>IFN-α</title>
            <description>Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentrations of Soluble Proteins: Plasma Basic Fibroblast Growth Factor (bFGF) That May be Associated With Tumor Proliferation or Angiogenesis</title>
          <description>Plasma concentrations of soluble proteins that may be associated with tumor proliferation or angiogenesis collected from a subset of patients were analyzed by enzyme-linked immunosorbent assay (ELISA) analysis. Soluble protein values: Baseline concentration (pM) and ratio to Baseline at each timepoint; ratio = plasma concentration of soluble protein (picograms per milliliter [pg/ml]) at timepoint / concentration of soluble protein (pg/ml) at baseline. Samples below the limit of quantitation and samples with insufficient volume available were excluded.</description>
          <population>Pharmacodynamic analyses performed at selected sites on AT population who had at least one PK (pharmacokinetic) sample; n = subjects with evaluable data at observation, SU011248 and INF-α treatment groups, respectively. Abbreviations: C = Cycle, D = Day, bFGF: basic fibroblast growth factor.</population>
          <units>pg/ml and ratio to Baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PLASMA bFGF: C2D28:C1D1 (n=14, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.760" spread="0.604"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLASMA bFGF: C3D1:C1D1 (n=12, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.582" spread="2.622"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLASMA bFGF: C3D28:C1D1 (n=12, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.671" spread="2.109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLASMA bFGF: C4D1:C1D1 (n=14, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.895" spread="4.252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLASMA bFGF: C4:D28:C1D1 (n=10, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.803" spread="0.799"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incremental Cost Effectiveness Ratio (ICER)</title>
        <description>Incremental cost effectiveness ratio (ICER) of sunitinib compared to IFN-a as first-line treatment for MRCC, defined as the ratio of the incremental cost of treatment over the incremental effectiveness; effectiveness measured as quality adjusted life year (QALY) gain. This objective was not addressed in the clinical study report, but an interim analysis of cost-effectiveness was presented separately. These results were not available for inclusion at the time of this posting.</description>
        <time_frame>post study measurement</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SU011248</title>
            <description>50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered.</description>
          </group>
          <group group_id="O2">
            <title>IFN-α</title>
            <description>Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Incremental Cost Effectiveness Ratio (ICER)</title>
          <description>Incremental cost effectiveness ratio (ICER) of sunitinib compared to IFN-a as first-line treatment for MRCC, defined as the ratio of the incremental cost of treatment over the incremental effectiveness; effectiveness measured as quality adjusted life year (QALY) gain. This objective was not addressed in the clinical study report, but an interim analysis of cost-effectiveness was presented separately. These results were not available for inclusion at the time of this posting.</description>
          <units>ratio</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="375"/>
                <count group_id="O2" value="375"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ctrough Concentrations of SU011248</title>
        <description>Subject observed Ctrough (trough drug) concentrations of SU011248 per cycle and study day determined by plasma trough samples collected from a subset of patients. Steady-state observed trough concentrations were dose corrected to the starting dose (reference dose) where appropriate. Concentrations below the limits of quantitation (BLQ) were set to 0. Ctrough = minimum (trough) plasma concentration (nanograms per milliliter [ng/mL]).</description>
        <time_frame>Day 28 of Cycle 1 to Cycle 4</time_frame>
        <population>As treated (AT) population: all patients who received at least 1 dose of study medication with treatment assignments designated according to actual study treatment received. Pharmacokinetic (PK) analyses were performed on the AT population who had at least one PK sample. n=number of subjects with evaluable trough samples.</population>
        <group_list>
          <group group_id="O1">
            <title>SU011248</title>
            <description>50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle. Intra-subject dose reduction to 35.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered.</description>
          </group>
        </group_list>
        <measure>
          <title>Ctrough Concentrations of SU011248</title>
          <description>Subject observed Ctrough (trough drug) concentrations of SU011248 per cycle and study day determined by plasma trough samples collected from a subset of patients. Steady-state observed trough concentrations were dose corrected to the starting dose (reference dose) where appropriate. Concentrations below the limits of quantitation (BLQ) were set to 0. Ctrough = minimum (trough) plasma concentration (nanograms per milliliter [ng/mL]).</description>
          <population>As treated (AT) population: all patients who received at least 1 dose of study medication with treatment assignments designated according to actual study treatment received. Pharmacokinetic (PK) analyses were performed on the AT population who had at least one PK sample. n=number of subjects with evaluable trough samples.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, Day 28 (n=31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.26" spread="31.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2, Day 28 (n=36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.59" spread="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3, Day 28 (n=36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.26" spread="24.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4, Day 28 (n=32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.05" spread="23.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose-Corrected: Cycle 1, Day 28 (n=24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.22" spread="31.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose-Corrected: Cycle 2, Day 28 (n=28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.90" spread="26.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose-Corrected: Cycle 3, Day 28 (n=27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.45" spread="29.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose-Corrected: Cycle 4, Day 28 (n=26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.31" spread="30.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ctrough Concentrations of Metabolite SU012662</title>
        <description>Subject observed Ctrough (trough drug) concentrations of active metabolite SU012662 per cycle and study day determined by plasma trough samples collected from a subset of patients. Steady-state observed trough concentrations were dose corrected to the starting dose (reference dose) where appropriate. Concentrations below the limits of quantitation (BLQ) were set to 0. Ctrough = minimum (trough) plasma concentration (nanograms per milliliter [ng/mL]).</description>
        <time_frame>Day 28 of Cycle 1 to Cycle 4</time_frame>
        <population>As treated (AT) population: all patients who received at least 1 dose of study medication with treatment assignments designated according to actual study treatment received. Pharmacokinetic (PK) analyses were performed on the AT population who had at least one PK sample. n=number of subjects with evaluable trough samples</population>
        <group_list>
          <group group_id="O1">
            <title>SU012662</title>
            <description>Active metabolite of SU011248</description>
          </group>
        </group_list>
        <measure>
          <title>Ctrough Concentrations of Metabolite SU012662</title>
          <description>Subject observed Ctrough (trough drug) concentrations of active metabolite SU012662 per cycle and study day determined by plasma trough samples collected from a subset of patients. Steady-state observed trough concentrations were dose corrected to the starting dose (reference dose) where appropriate. Concentrations below the limits of quantitation (BLQ) were set to 0. Ctrough = minimum (trough) plasma concentration (nanograms per milliliter [ng/mL]).</description>
          <population>As treated (AT) population: all patients who received at least 1 dose of study medication with treatment assignments designated according to actual study treatment received. Pharmacokinetic (PK) analyses were performed on the AT population who had at least one PK sample. n=number of subjects with evaluable trough samples</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, Day 28 (n=31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.10" spread="17.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2, Day 28 (n=36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.35" spread="15.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3, Day 28 (n=36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.11" spread="16.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4, Day 28 (n=32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.11" spread="12.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose-Corrected: Cycle 1, Day 28 (n=24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.21" spread="19.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose-Corrected: Cycle 2, Day 28 (n=28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.32" spread="13.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose-Corrected: Cycle 3, Day 28 (n=27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.04" spread="19.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose-Corrected: Cycle 4, Day 28 (n=26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.99" spread="16.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ctrough Concentrations of SU011248 and Active Metabolite SU012662</title>
        <description>Subject observed Ctrough (trough drug) concentrations of total drug (SU011248 and its active metabolite SU012662) per cycle and study day determined by plasma trough samples collected from a subset of patients. Steady-state observed trough concentrations were dose corrected to the starting dose (reference dose) where appropriate. Concentrations below the limits of quantitation (BLQ) were set to 0. Ctrough = minimum (trough) plasma concentration (nanograms per milliliter [ng/mL]).</description>
        <time_frame>Day 28 of Cycle 1 to Cycle 4</time_frame>
        <population>As treated (AT) population: all patients who received at least 1 dose of study medication with treatment assignments designated according to actual study treatment received. Pharmacokinetic (PK) analyses were performed on the AT population who had at least one PK sample. n=number of subjects with evaluable trough samples at observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Total Drug: SU011248 and SU012662</title>
            <description>SU011248 and active metabolite SU012662</description>
          </group>
        </group_list>
        <measure>
          <title>Ctrough Concentrations of SU011248 and Active Metabolite SU012662</title>
          <description>Subject observed Ctrough (trough drug) concentrations of total drug (SU011248 and its active metabolite SU012662) per cycle and study day determined by plasma trough samples collected from a subset of patients. Steady-state observed trough concentrations were dose corrected to the starting dose (reference dose) where appropriate. Concentrations below the limits of quantitation (BLQ) were set to 0. Ctrough = minimum (trough) plasma concentration (nanograms per milliliter [ng/mL]).</description>
          <population>As treated (AT) population: all patients who received at least 1 dose of study medication with treatment assignments designated according to actual study treatment received. Pharmacokinetic (PK) analyses were performed on the AT population who had at least one PK sample. n=number of subjects with evaluable trough samples at observation.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, Day 28 (n=31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.36" spread="46.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2, Day 28 (n=36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.94" spread="41.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3, Day 28 (n=36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.37" spread="38.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4, Day 28 (n=32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.15" spread="34.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose-Corrected: Cycle 1, Day 28 (n=24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.43" spread="48.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose-Corrected: Cycle 2, Day 28 (n=28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.22" spread="36.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose-Corrected: Cycle 3, Day 28 (n=27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.49" spread="45.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose-Corrected: Cycle 4, Day 28 (n=27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.30" spread="44.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>SU011248</title>
          <description>50 mg taken orally once a day for 4 weeks followed by a 2-week off treatment cycle to form a 6-week treatment cycle. Intra-subject dose reduction to 37.5 mg/day and 25 mg/day was allowed depending on type and severity of toxicity encountered.</description>
        </group>
        <group group_id="E2">
          <title>IFN-α</title>
          <description>Subcutaneous (SC) injection in 6-week cycles on 3 non-consecutive days per week; 3 million units (MU) per dose Week 1; 6 MU per dose Week 2; 9 MU per dose Week 3 until completion of therapy or development of toxicity.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (v11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="170" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="360"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Idiopathic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Thrombotic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Retinal artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Gastrointestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Glossodynia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Intestinal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Tongue oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Condition aggravated</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Performance status decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="360"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary tract disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Pleural infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Pyothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Dislocation of joint prosthesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Brain herniation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Electrocardiogram change</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Urine output decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Hypercreatinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Intracranial tumour haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Monoparesis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Cerebellar syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Cerebral haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Facial palsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Incoherent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Paresis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Reversible posterior leukoencephalopathy syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Motor dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Emotional disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Urinary bladder haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="360"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Diabetic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Palmar—plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Stevens—Johnson syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Bone graft</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Hepatectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Inguinal hernia repair</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Pleurectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Vertebroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Malignant hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Superior vena caval occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (v11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="368" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="344" subjects_at_risk="360"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="360"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="360"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="245" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="128" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Glossodynia</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="215" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="146" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="113" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="144" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="360"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="111" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="230" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="200" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="134" subjects_at_risk="360"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="360"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="360"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="154" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="112" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="360"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="360"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="174" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="360"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="360"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="360"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Hair colour changes</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Palmar—plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="109" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Skin discolouration</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="360"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="125" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="360"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of &lt; 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), &lt; 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.govCallCenter@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

